,variant_id,variant_civic_url,gene,entrez_id,variant,summary,variant_groups,chromosome,start,stop,reference_bases,variant_bases,representative_transcript,ensembl_version,reference_build,chromosome2,start2,stop2,representative_transcript2,variant_types,hgvs_expressions,last_review_date,civic_variant_evidence_score,allele_registry_id,clinvar_ids,variant_aliases,assertion_ids,assertion_civic_urls,aa_position
3,3,https://civic.genome.wustl.edu/links/variants/4,AKT1,207,E17K,"AKT1 E17K is a recurrent mutation that has been observed in breast, colorectal, lung, and ovarian cancer. It has been convincingly shown to be an activating mutation resulting in PI3K/AKT/mTOR pathway activity. It has been suggested that this mutation decreases the cell's sensitivity to AKT1 allosteric kinase inhibitors. This, and other AKT1 mutations, are the subject of much research and development for therapeutics.",,14,105246551.0,105246551.0,C,T,ENST00000407796.2,75.0,GRCh37,,,,,missense_variant,"NC_000014.8:g.105246551C>T,NM_001014432.1:c.49G>A,NP_001014432.1:p.Glu17Lys,ENST00000407796.2:c.49G>A",2018-11-30 14:44:59 UTC,32.5,CA123660,13983,"GLU17LYS,RS34409589",,,
7,7,https://civic.genome.wustl.edu/links/variants/8,ALK,238,F1174L,"ALK F1174L has been observed as recurrent in neuroblastoma, non-small cell lung cancer (NSCLC), and other cancer types. Neuroblastoma cells containing this mutation have shown resistance to low doses of criztonib. However, increased dosage can overcome this resistance in cell lines studies. TAE684 has also proven effective in both NSCLC and neuroblastoma F1174L containing cells.",Crizotinib Resistance,2,29443695.0,29443695.0,G,T,ENST00000389048.3,75.0,GRCh37,,,,,missense_variant,"NM_004304.4:c.3522C>A,NP_004295.2:p.Phe1174Leu,NC_000002.11:g.29443695G>T,ENST00000389048.3:c.3522C>A",2018-11-30 14:45:01 UTC,33.5,CA279586,217851,"PHE1174LEU,RS863225281",,,
8,8,https://civic.genome.wustl.edu/links/variants/9,ALK,238,R1275Q,"ALK R1275Q has been observed as a recurrent mutation in  neuroblastoma, non-small cell lung cancer (NSCLC), as well as other cancer types. Neuroblastoma cells with this mutation have shown sensitivity to the ALK-inhibitor TAE684. This and the geldanamycin deriviative 17-DMAG have been shown to be effective in NSCLC cell lines.",,2,29432664.0,29432664.0,C,T,ENST00000389048.3,75.0,GRCh37,,,,,missense_variant,"NM_004304.4:c.3824G>A,NP_004295.2:p.Arg1275Gln,NC_000002.11:g.29432664C>T,ENST00000389048.3:c.3824G>A",2018-11-30 14:44:59 UTC,23.0,CA341482,18083,"ARG1275GLN,RS113994087",,,
9,9,https://civic.genome.wustl.edu/links/variants/10,ARAF,369,S214C,"ARAF S214C has been found to be a recurrent oncogenic mutation in non-small cell lung cancer. It has been shown to confer sensitivity to sorafenib and trametenib in cell lines. In a case study of advanced stage lung adenocarcinoma harboring this mutation, sorafenib also acheived near-complete clinical remission. This case has brought more interest to the variant from a research and clinical perspective.",,X,47426121.0,47426121.0,C,G,ENST00000377045.4,75.0,GRCh37,,,,,missense_variant,"NC_000023.10:g.47426121C>G,NM_001654.4:c.641C>G,NP_001645.1:p.Ser214Cys,ENST00000377045.4:c.641C>G",2018-11-30 14:43:04 UTC,11.0,CA16602595,376137,"SER214CYS,RS1057519786",,,
10,10,https://civic.genome.wustl.edu/links/variants/11,BRAF,673,V600D,"Patients harboring mutations in valine 600 residue of BRAF have been shown to be sensitive to dabrafenib. For more information on the V600 locus, see the V600E entry.",Other V600's,7,140453135.0,140453136.0,CA,AT,ENST00000288602.6,75.0,GRCh37,,,,,missense_variant,"NC_000007.13:g.140453135_140453136delinsAT,NM_004333.4:c.1799_1800delTGinsAT,NP_004324.2:p.Val600Asp,ENST00000288602.6:c.1799_1800delTGinsAT",2018-11-30 14:45:24 UTC,25.0,CA16602419,375939,"RS121913377,VAL600ASP",,,
11,11,https://civic.genome.wustl.edu/links/variants/12,BRAF,673,V600E,"BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.",,7,140453136.0,140453136.0,A,T,ENST00000288602.6,75.0,GRCh37,,,,,missense_variant,"NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A",2019-02-28 18:34:09 UTC,1019.0,CA123643,13961,"RS113488022,VAL600GLU","10,12,7,20",https://civic.genome.wustl.edu/links/assertions/10,
12,12,https://civic.genome.wustl.edu/links/variants/13,BRAF,673,V600E+V600M,"A case study of a single patient harboring both a V600E and a V600M mutation, dabrafenib was shown to acheive clinical response.",Other V600's,7,140453135.0,140453137.0,,,ENST00000288602.6,75.0,GRCh37,,,,,missense_variant,,2017-12-01 14:40:28 UTC,7.5,,"44815,13961",,,,
28,28,https://civic.genome.wustl.edu/links/variants/32,DNMT3A,1788,R882,"DNMT3A R882 mutations are associated with cytogenetically normal acute myeloid leukemia (CN-AML) with R882H as the most common form. Mutations in DNMT3A have largely been associated with poorer prognosis, however this is not consistent across all studies. This may be a result of patient age or combining R882 and non-R882 mutations during analysis as studies have indicated independent mechanisms of action and differential prognostic implications for these mutation types. One study that independently analyzed R882 and non-R882 mutations showed R882 mutations were associated with poorer prognosis than patients with wildtype and non-R882 mutations, but only in older patients with AML.",,2,25457241.0,25457243.0,,,ENST00000264709.3,75.0,GRCh37,,,,,missense_variant,,2017-12-01 14:40:28 UTC,525.0,,"375882,375883,375884,375879,375880,375881",R693,,,
29,29,https://civic.genome.wustl.edu/links/variants/33,EGFR,1956,L858R,"EGFR L858R has long been recognized as a functionally significant mutation in cancer, and is one of the most prevalent single mutations in lung cancer. Best described in non-small cell lung cancer (NSCLC), the mutation seems to confer sensitivity to first and second generation TKI's like gefitinib and neratinib. NSCLC patients with this mutation treated with TKI's show increased overall and progression-free survival, as compared to chemotherapy alone. Third generation TKI's are currently in clinical trials that specifically focus on mutant forms of EGFR, a few of which have shown efficacy in treating patients that failed to respond to earlier generation TKI therapies.",,7,55259515.0,55259515.0,T,G,ENST00000275493.2,75.0,GRCh37,,,,,missense_variant,"NC_000007.13:g.55259515T>G,NM_005228.4:c.2573T>G,ENST00000275493.2:c.2573T>G,NP_005219.2:p.Leu858Arg",2019-02-28 18:57:21 UTC,328.5,CA126713,16609,"LEU858ARG,RS121434568","6,5",https://civic.genome.wustl.edu/links/assertions/6,
30,30,https://civic.genome.wustl.edu/links/variants/34,EGFR,1956,T790M,"EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.",EGFR TKI Resistance,7,55249071.0,55249071.0,C,T,ENST00000275493.2,75.0,GRCh37,,,,,missense_variant,"ENST00000275493.2:c.2369C>T,NM_005228.4:c.2369C>T,NP_005219.2:p.Thr790Met,NC_000007.13:g.55249071C>T",2018-11-30 14:45:31 UTC,376.25,CA090928,16613,"THR790MET,RS121434569",,,
32,32,https://civic.genome.wustl.edu/links/variants/36,ERBB2,2064,D769Y,"ERBB2 D769Y was one of the first ERBB2 variants to be functionally classified (Bose et al., 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.",HER2 Activating,17,37880261.0,37880261.0,G,T,ENST00000269571.5,75.0,GRCh37,,,,,missense_variant,"ENST00000269571.5:c.2305G>T,NC_000017.10:g.37880261G>T,NM_004448.3:c.2305G>T,NP_004439.2:p.Asp769Tyr",2018-11-30 14:44:52 UTC,4.0,CA16602466,375992,"D739Y,D754Y,RS121913468,ASP769TYR,D769Y,ASP754TYR,ASP739TYR",,,
34,34,https://civic.genome.wustl.edu/links/variants/38,ERBB2,2064,G309A,"ERBB2 G309A was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.",HER2 Activating,17,37868205.0,37868205.0,G,C,ENST00000269571.5,75.0,GRCh37,,,,,missense_variant,"ENST00000269571.5:c.926G>C,NC_000017.10:g.37868205G>C,NM_004448.3:c.926G>C,NP_004439.2:p.Gly309Ala",2018-11-30 14:43:04 UTC,5.0,CA16602660,376205,"GLY309ALA,GLY279ALA,GLY294ALA,G294A,G279A,RS1057519787",,,
35,35,https://civic.genome.wustl.edu/links/variants/39,ERBB2,2064,L755S,"ERBB2 L755S was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was not shown to be an activating mutation, unlike many of the other variants queried. This mutation was also shown to confer resistance to the tyrosine kinase inhibitor lapatinib in MCF10A cell lines.",,17,37880220.0,37880220.0,T,C,ENST00000269571.5,75.0,GRCh37,,,,,missense_variant,"ENST00000269571.5:c.2264T>C,NC_000017.10:g.37880220T>C,NM_004448.3:c.2264T>C,NP_004439.2:p.Leu755Ser",2018-11-30 14:45:04 UTC,14.0,CA16602502,,,,,
36,36,https://civic.genome.wustl.edu/links/variants/40,ERBB2,2064,L755W,"ERBB2 L755W was one of the first ERBB2 variants to be functionally classified (Bose et al., 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.",,17,37880220.0,37880220.0,T,G,ENST00000269571.5,75.0,GRCh37,,,,,missense_variant,"ENST00000269571.5:c.2264T>G,NC_000017.10:g.37880220T>G,NM_004448.3:c.2264T>G,NP_004439.2:p.Leu755Trp",2018-11-30 14:43:24 UTC,5.0,CA16602786,376343,"LEU755TRP,L725W,L740W",,,
38,38,https://civic.genome.wustl.edu/links/variants/42,ERBB2,2064,R678Q,"ERBB2 R678Q was shown to have NO functional effect in tissue culture assay (Bose et al 2013). This conclusion was confirmed by a second, independent lab.",,17,37879658.0,37879658.0,G,A,ENST00000269571.5,75.0,GRCh37,,,,,missense_variant,"ENST00000269571.5:c.2033G>A,NC_000017.10:g.37879658G>A,NM_004448.3:c.2033G>A,NP_004439.2:p.Arg678Gln",2018-11-30 14:43:31 UTC,5.0,CA16602787,376344,"ARG678GLN,R648Q,R663Q",,,
39,39,https://civic.genome.wustl.edu/links/variants/43,ERBB2,2064,R896C,"ERBB2 R896C was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.",HER2 Activating,17,37881616.0,37881616.0,C,T,ENST00000269571.5,75.0,GRCh37,,,,,missense_variant,"ENST00000269571.5:c.2686C>T,NC_000017.10:g.37881616C>T,NM_004448.3:c.2686C>T,NP_004439.2:p.Arg896Cys",2018-11-30 14:43:04 UTC,5.0,CA8534359,375995,"ARG896CYS,R866C,R881C,RS758222990",,,
40,40,https://civic.genome.wustl.edu/links/variants/44,ERBB2,2064,V777L,"ERBB2 V777L was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.",HER2 Activating,17,37881000.0,37881000.0,G,T,ENST00000269571.5,75.0,GRCh37,,,,,missense_variant,"NM_004448.3:c.2329G>T,NP_004439.2:p.Val777Leu,ENST00000269571.5:c.2329G>T,NC_000017.10:g.37881000G>T",2018-11-30 14:43:13 UTC,9.0,CA135387,44991,"V747L,V762L,VAL777LEU,RS121913471",,,
41,41,https://civic.genome.wustl.edu/links/variants/45,ERBB2,2064,V842I,"ERBB2 V842I was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.",HER2 Activating,17,37881332.0,37881332.0,G,A,ENST00000269571.5,75.0,GRCh37,,,,,missense_variant,"ENST00000269571.5:c.2524G>A,NM_004448.3:c.2524G>A,NP_004439.2:p.Val842Ile,NC_000017.10:g.37881332G>A",2018-11-30 14:43:19 UTC,9.0,CA16602468,375994,"VAL842ILE,V812I,V827I,VAL812ILE,VAL827ILE",,,
42,42,https://civic.genome.wustl.edu/links/variants/46,ESR1,2099,L536Q,"ESR1 biology has become a central focus in breast cancer therapy. In ER+ tumors, mutations in the ESR1 ligand binding domain have been shown to confer resistance to hormone therapy. This evidence has led to an increased use of targeted sequencing of the estrogen receptor in breast and ovarian cancer. Y536Q is one of these ligand binding domain mutations, and is commonly implicated in this hormone resistance. Preliminary data suggests ER-degrading agents, such as fulvestrant, may be beneficial in treating ESR1 mutant, hormone resistant breast cancers.",ESR1 Ligand-Binding Domain,6,152419920.0,152419921.0,TC,AG,ENST00000440973.1,75.0,GRCh37,,,,,missense_variant,NC_000006.11:g.152419920_152419921delinsAG,2018-11-30 14:45:01 UTC,8.0,CA645542628,NONE FOUND,LEU536GLN,,,
43,43,https://civic.genome.wustl.edu/links/variants/47,ESR1,2099,D538G,"ESR1 biology has become a central focus in breast cancer therapy. In ER+ tumors, mutations in the ESR1 ligand binding domain have been shown to confer resistance to hormone therapy. This evidence has led to an increased use of targeted sequencing of the estrogen receptor in breast and ovarian cancer. D538G is one of these ligand binding domain mutations, and is commonly implicated in this hormone resistance. Preliminary data suggests ER-degrading agents, such as fulvestrant, may be beneficial in treating ESR1 mutant, hormone resistant breast cancers.",ESR1 Ligand-Binding Domain,6,152419926.0,152419926.0,A,G,ENST00000206249.3,75.0,GRCh37,,,,,missense_variant,"ENST00000206249.3:c.1613A>G,NC_000006.11:g.152419926A>G",2018-11-30 14:45:02 UTC,18.0,CA366085705,NONE FOUND,ASP538GLY,,,
44,44,https://civic.genome.wustl.edu/links/variants/48,ESR1,2099,Y537C,"ESR1 biology has become a central focus in breast cancer therapy. In ER+ tumors, mutations in the ESR1 ligand binding domain have been shown to confer resistance to hormone therapy. This evidence has led to an increased use of targeted sequencing of the estrogen receptor in breast and ovarian cancer. Y537C is one of these ligand binding domain mutations, and is commonly implicated in this hormone resistance. Preliminary data suggests ER-degrading agents, such as fulvestrant, may be beneficial in treating ESR1 mutant, hormone resistant breast cancers.",ESR1 Ligand-Binding Domain,6,152419923.0,152419923.0,A,G,ENST00000206249.3,75.0,GRCh37,,,,,missense_variant,"ENST00000206249.3:c.1610A>G,NC_000006.11:g.152419923A>G",2018-11-30 14:45:04 UTC,8.0,CA366085697,NONE FOUND,GLY537CYS,,,
45,45,https://civic.genome.wustl.edu/links/variants/49,ESR1,2099,Y537N,"ESR1 biology has become a central focus in breast cancer therapy. In ER+ tumors, mutations in the ESR1 ligand binding domain have been shown to confer resistance to hormone therapy. This evidence has led to an increased use of targeted sequencing of the estrogen receptor in breast and ovarian cancer. Y537N is one of these ligand binding domain mutations, and is commonly implicated in this hormone resistance. Preliminary data suggests ER-degrading agents, such as fulvestrant, may be beneficial in treating ESR1 mutant, hormone resistant breast cancers.",ESR1 Ligand-Binding Domain,6,152419922.0,152419922.0,T,A,ENST00000206249.3,75.0,GRCh37,,,,,missense_variant,"ENST00000206249.3:c.1609T>A,NC_000006.11:g.152419922T>A",2018-11-30 14:45:01 UTC,8.0,CA366085693,NONE FOUND,GLY537ASN,,,
46,46,https://civic.genome.wustl.edu/links/variants/50,ESR1,2099,Y537S,"ESR1 biology has become a central focus in breast cancer therapy. In ER+ tumors, mutations in the ESR1 ligand binding domain have been shown to confer resistance to hormone therapy. This evidence has led to an increased use of targeted sequencing of the estrogen receptor in breast and ovarian cancer. Y537S is one of these ligand binding domain mutations, and is commonly implicated in this hormone resistance. Preliminary data suggests ER-degrading agents, such as fulvestrant, may be beneficial in treating ESR1 mutant, hormone resistant breast cancers.",ESR1 Ligand-Binding Domain,6,152419923.0,152419923.0,A,C,ENST00000206249.3,75.0,GRCh37,,,,,missense_variant,"ENST00000206249.3:c.1610A>C,NC_000006.11:g.152419923A>C",2018-11-30 14:45:03 UTC,8.0,CA366085696,NONE FOUND,GLY537SER,,,
54,54,https://civic.genome.wustl.edu/links/variants/59,IDH1,3417,R132C,"IDH1 R132 mutations have been observed in a number of cancer types, and appear to behave quite differently in different environments. In myelodysplastic syndromes and acute myeloid leukemia (AML), IDH1 R132 mutations have been shown to be associated with worse outcome and shorter overall survival. They have also been linked to cytogenetically normal AML, an intermediate risk subtype of the disease. However, in glioblastoma and astrocytoma, patients with IDH1 mutations have shown better overall survival than patients with wild-type IDH1. Also in contrast to AML, in glioblastoma, IDH1 mutations have been associated with the specific cytogenetic abnormalities, 1p and 19q deletions.",,2,209113113.0,209113113.0,G,A,ENST00000415913.1,75.0,GRCh37,,,,,missense_variant,"NM_005896.3:c.394C>T,NP_005887.2:p.Arg132Cys,NC_000002.11:g.209113113G>A,ENST00000415913.1:c.394C>T",2018-11-30 14:45:03 UTC,63.0,CA16602374,375891,"RS121913499,ARG132CYS",,,
56,56,https://civic.genome.wustl.edu/links/variants/63,IDH2,3418,R172K,"IDH2 mutations have been observed in a number of hematologic malignancies. In acute myeloid leukemia, the R172K mutation has been linked with poorer prognosis and worse overall survival than IDH2 wild-type patients. However, in myelodisplastic syndromes, studies did not find a prognostic association between this variant and patient outcomes.",,15,90631838.0,90631838.0,C,T,ENST00000330062.3,75.0,GRCh37,,,,,missense_variant,"NM_002168.3:c.515G>A,NP_002159.2:p.Arg172Lys,NC_000015.9:g.90631838C>T,ENST00000330062.3:c.515G>A",2018-11-30 14:43:17 UTC,35.0,CA16602462,375987,"ARG172LYS,R120K,RS121913503",,,
67,67,https://civic.genome.wustl.edu/links/variants/78,KRAS,3845,G12C,"While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.",EGFR TKI Resistance,12,25398285.0,25398285.0,C,A,ENST00000256078.4,75.0,GRCh37,,,,,missense_variant,"NM_004985.4:c.34G>T,NP_004976.2:p.Gly12Cys,NC_000012.11:g.25398285C>A,ENST00000256078.4:c.34G>T",2018-11-30 14:43:29 UTC,74.0,CA122528,12578,"GLY12CYS,RS121913530",,,
72,72,https://civic.genome.wustl.edu/links/variants/83,MAP2K1,5604,Q56P,MAP2K1 Q56P is a recurrent mutation in melanoma and gastric cancer. This mutation has been shown to confer considerable resistance to AZD6244 treatment of melanoma cell lines.,,15,66727451.0,66727451.0,A,C,ENST00000307102.5,75.0,GRCh37,,,,,missense_variant,"ENST00000307102.5:c.167A>C,NC_000015.9:g.66727451A>C,NM_002755.3:c.167A>C,NP_002746.1:p.Gln56Pro",2018-11-30 14:43:05 UTC,3.0,CA16602453,375978,GLN56PRO,,,
77,77,https://civic.genome.wustl.edu/links/variants/93,NRAS,4893,G13D,"While the NRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated.",,1,115258744.0,115258744.0,C,T,ENST00000369535.4,75.0,GRCh37,,,,,missense_variant,"NM_002524.4:c.38G>A,NP_002515.1:p.Gly13Asp,NC_000001.10:g.115258744C>T,ENST00000369535.4:c.38G>A",2018-11-30 14:43:05 UTC,5.0,CA123620,13901,"GLY13ASP,RS121434596",,,
78,78,https://civic.genome.wustl.edu/links/variants/94,NRAS,4893,Q61,"NRAS Q61 mutations have been found in multiple myeloma, gastrointestinal stromal tumors, melanoma, and others. Two melanoma patients, each harboring mutations at this locus (Q61L and Q61R), responded to treatment with the akylating agent temozolomide. However, in colorectal cancer patients, mutations at this locus have been shown to confer resistance to cetuximab. The prognostic impact of mutations at this locus is currently under study.",,1,115256528.0,115256530.0,,,ENST00000369535.4,75.0,GRCh37,,,,,missense_variant,,2019-02-10 01:56:04 UTC,105.0,,"375875,280409,373003,375871,375874,13900,73058",GLN61,,,
79,79,https://civic.genome.wustl.edu/links/variants/95,NRAS,4893,Q61L,"NRAS Q61 mutations have been found in multiple myeloma, gastrointestinal stromal tumors, melanoma, and others. A melanoma patient harboring a mutation at this locus responded to treatment with the akylating agent temozolomide. However, in colorectal cancer patients, mutations at this locus have been shown to confer resistance to cetuximab. The prognostic impact of mutations at this locus is currently under study.",,1,115256529.0,115256529.0,T,A,ENST00000369535.4,75.0,GRCh37,,,,,missense_variant,"NP_002515.1:p.Gln61Leu,NC_000001.10:g.115256529T>A,NM_002524.4:c.182A>T,ENST00000369535.4:c.182A>T",2018-11-30 14:42:56 UTC,5.0,CA16602361,375874,"GLN61LEU,RS11554290",,,
81,81,https://civic.genome.wustl.edu/links/variants/98,PDGFRA,5156,D842I,"PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).",Imatinib Resistance,4,55152092.0,55152093.0,GA,AT,ENST00000257290.5,75.0,GRCh37,,,,,missense_variant,"ENST00000257290.5:c.2524_2525delinsAT,NC_000004.11:g.55152092_55152093delinsAT,NP_006197.1:p.Asp842Ile,NM_006206.5:c.2524_2525delGAinsAT",2018-11-30 14:43:06 UTC,4.0,CA16602522,376055,ASP842ILE,,,
82,82,https://civic.genome.wustl.edu/links/variants/99,PDGFRA,5156,D842V,"PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. Exogenous expression of the A842V mutation resulted in constitutive tyrosine phosphorylation of PDGFRA in the absence of ligand in 293T cells and cytokine-independent proliferation of the IL-3-dependent Ba/F3 cell line, both evidence that this is an activating mutation. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).",Imatinib Resistance,4,55152093.0,55152093.0,A,T,ENST00000257290.5,75.0,GRCh37,,,,,missense_variant,"NM_006206.4:c.2525A>T,NP_006197.1:p.Asp842Val,ENST00000257290.5:c.2525A>T,NC_000004.11:g.55152093A>T",2019-04-26 20:34:18 UTC,93.0,CA123194,13543,"ASP842VAL,RS121908585",,,
83,83,https://civic.genome.wustl.edu/links/variants/100,PDGFRA,5156,D842Y,"PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).",Imatinib Resistance,4,55152092.0,55152092.0,G,T,ENST00000257290.5,75.0,GRCh37,,,,,missense_variant,"ENST00000257290.5:c.2524G>T,NC_000004.11:g.55152092G>T,NM_006206.5:c.2524G>T,NP_006197.1:p.Asp842Tyr",2018-11-30 14:43:17 UTC,4.0,CA16602703,376250,"ASP842TYR,RS121913265",,,
85,85,https://civic.genome.wustl.edu/links/variants/102,PDGFRA,5156,DI842-843VM,"PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. The DI842-843VM variant is the result of a double point mutation. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).",Imatinib Resistance,4,55152093.0,55152097.0,ACATC,TCATG,ENST00000257290.5,75.0,GRCh37,,,,,missense_variant,NC_000004.11:g.55152093_55152097delinsTCATG,2018-11-30 14:43:00 UTC,4.0,CA658820703,NONE FOUND,,,,
86,86,https://civic.genome.wustl.edu/links/variants/103,PIK3CA,5290,E542K,"PIK3CA E545K/E542K are the second most recurrent PIK3CA mutations in breast cancer, and are highly recurrent mutations in many other cancer types. E545K, and possibly the other mutations in the E545 region, may present patients with a poorer prognosis than patients with other PIK3CA variants or wild-type PIK3CA. There is also data to suggest that E545/542 mutations may confer resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies for variants in PIK3CA are still in early clinical trial phases.",,3,178936082.0,178936082.0,G,A,ENST00000263967.3,75.0,GRCh37,,,,,missense_variant,"NM_006218.3:c.1624G>A,NP_006209.2:p.Glu542Lys,ENST00000263967.3:c.1624G>A,NC_000003.11:g.178936082G>A",2018-11-30 14:43:11 UTC,65.5,CA333572,31944,"GLU542LYS,RS121913273",,,
87,87,https://civic.genome.wustl.edu/links/variants/104,PIK3CA,5290,E545K,"PIK3CA E545K/E542K are the second most recurrent PIK3CA mutations in breast cancer, and are highly recurrent mutations in many other cancer types. E545K, and possibly the other mutations in the E545 region, may present patients with a poorer prognosis than patients with either patients with other PIK3CA variant or wild-type PIK3CA. There is also data to suggest that E545/542 mutations may confer resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies for variants in PIK3CA are still in early clinical trial phases.",,3,178936091.0,178936091.0,G,A,ENST00000263967.3,75.0,GRCh37,,,,,missense_variant,"NM_006218.3:c.1633G>A,NP_006209.2:p.Glu545Lys,ENST00000263967.3:c.1633G>A,NC_000003.11:g.178936091G>A",2019-01-26 23:07:09 UTC,46.0,CA123334,13655,"GLU545LYS,RS104886003",,,
93,93,https://civic.genome.wustl.edu/links/variants/112,RET,5979,C634W,"RET C634W has been implicated as an alternate mechanism of activating RET in medullary thyroid cancer. While there currently are no RET-specific inhibiting agents, promiscuous kinase inhibitors have seen some success in treating RET overactivity. Data suggests however, that the C634W mutation may lead to drug resistance, especially against the VEGFR-inhibitor motesanib.",Motesanib Resistance,10,43609950.0,43609950.0,C,G,ENST00000355710.3,75.0,GRCh37,,,,,missense_variant,"NM_020975.4:c.1902C>G,NP_065681.1:p.Cys634Trp,ENST00000355710.3:c.1902C>G,NC_000010.10:g.43609950C>G",2018-11-30 14:45:03 UTC,3.0,CA008378,13918,CYS634TRP,,,
94,94,https://civic.genome.wustl.edu/links/variants/113,RET,5979,M918T,"RET M819T is the most common somatically acquired mutation in medullary thyroid cancer (MTC). While there currently are no RET-specific inhibiting agents, promiscuous kinase inhibitors have seen some success in treating RET overactivity. Data suggests however, that the M918T mutation may lead to drug resistance, especially against the VEGFR-inhibitor motesanib. It has also been suggested that RET M819T leads to more aggressive MTC with a poorer prognosis.",Motesanib Resistance,10,43617416.0,43617416.0,T,C,ENST00000355710.3,75.0,GRCh37,,,,,missense_variant,"NM_020975.4:c.2753T>C,NP_065681.1:p.Met918Thr,ENST00000355710.3:c.2753T>C,NC_000010.10:g.43617416T>C",2018-11-30 14:43:07 UTC,66.0,CA009082,13919,"MET918THR,RS74799832",,,
95,95,https://civic.genome.wustl.edu/links/variants/114,SF3B1,23451,K666N,"SF3B1 K666N is a variant found in myelodysplastic syndromes, chronic leukemias, and more recently, breast cancer. This somatic mutation has been linked to better overall outcome and event-free survival in MDS patients.",HEAT domain mutation,2,198267359.0,198267359.0,C,A,ENST00000335508.6,75.0,GRCh37,,,,,missense_variant,"NM_012433.3:c.1998G>T,NP_036565.2:p.Lys666Asn,ENST00000335508.6:c.1998G>T,NC_000002.11:g.198267359C>A",2018-11-30 14:43:08 UTC,2.0,CA280929,219098,"LYS666ASN,RS377023736",,,
96,96,https://civic.genome.wustl.edu/links/variants/116,TP53,7157,R175H,"While loss-of-function events in TP53 are very common in cancer, the R175H variant seems not only to result in loss of tumor-suppression, but also acts as a gain-of-function mutation that promotes tumorigenesis in mouse models. Cell lines harboring this mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been shown that the R175H mutation is correlated with worse overall survival than wild-type TP53, but is not as detrimental as the R248W variant.",,17,7578406.0,7578406.0,C,T,ENST00000269305.4,75.0,GRCh37,,,,,missense_variant,"NM_000546.5:c.524G>A,NP_000537.3:p.Arg175His,NC_000017.10:g.7578406C>T,ENST00000269305.4:c.524G>A",2018-11-30 14:45:03 UTC,22.0,CA000251,12374,"ARG175HIS,RS28934578",,,
98,98,https://civic.genome.wustl.edu/links/variants/118,TP53,7157,R248W,"While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival.",,17,7577539.0,7577539.0,G,A,ENST00000269305.4,75.0,GRCh37,,,,,missense_variant,"NM_000546.5:c.742C>T,NP_000537.3:p.Arg248Trp,NC_000017.10:g.7577539G>A,ENST00000269305.4:c.742C>T",2018-11-30 14:43:08 UTC,19.0,CA000382,12347,"ARG248TRP,RS121912651",,,
100,100,https://civic.genome.wustl.edu/links/variants/121,TP53,7157,R273C,"While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.",,17,7577121.0,7577121.0,G,A,ENST00000269305.4,75.0,GRCh37,,,,,missense_variant,"NM_000546.5:c.817C>T,NP_000537.3:p.Arg273Cys,NC_000017.10:g.7577121G>A,ENST00000269305.4:c.817C>T",2018-12-18 22:59:33 UTC,41.5,CA000432,43594,"ARG273CYS,RS121913343",,,
101,101,https://civic.genome.wustl.edu/links/variants/122,TP53,7157,R273H,"While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.",,17,7577120.0,7577120.0,C,T,ENST00000269305.4,75.0,GRCh37,,,,,missense_variant,"NM_000546.5:c.818G>A,NP_000537.3:p.Arg273His,NC_000017.10:g.7577120C>T,ENST00000269305.4:c.818G>A",2018-11-30 14:45:21 UTC,34.0,CA000434,12366,"ARG273HIS,RS28934576",,,
104,104,https://civic.genome.wustl.edu/links/variants/127,U2AF1,7307,Q157P/R,"U2AF1 Q157P/R has been shown to be a recurrent mutation in acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and lung adenocarcinomas. This mutation is less common than the S34F mutation, occurs in the second zinc finger domain of U2AF1 and has been demonstrated to alter splicing. The impact of U2AF1 mutations on overall survival in MDS has been debated, however, patients with U2AF1 mutations were shown to be at an increased risk of transformation to secondary AML. The presence of this mutation was not associated with a specific prognostic outcome in AML when compared to U2AF1 wildtype patients.",,21,44514777.0,44514777.0,T,G,ENST00000291552.4,75.0,GRCh37,,,,,missense_variant,NC_000021.8:g.44514777T>G,2017-12-01 14:40:29 UTC,50.0,,,,,,
105,105,https://civic.genome.wustl.edu/links/variants/128,U2AF1,7307,S34Y/F,"U2AF1 S34Y/F has been shown to be a recurrent mutation in acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and lung adenocarcinomas. This mutation is the most commonly identified variant in MDS, occurs in the first zinc finger domain of U2AF1 and has been demonstrated to alter splicing. The impact of U2AF1 mutations on overall survival in MDS has been debated, however, patients with U2AF1 mutations were shown to be at an increased risk of transformation to secondary AML. The presence of this mutation was not associated with a specific prognostic outcome in AML when compared to U2AF1 wildtype patients.",,21,44524456.0,44524456.0,G,A,ENST00000291552.4,75.0,GRCh37,,,,,missense_variant,NC_000021.8:g.44524456G>A,2017-12-01 14:40:29 UTC,40.0,,,,,,
112,112,https://civic.genome.wustl.edu/links/variants/135,NOTCH1,4851,D1642H,"Activating mutations in NOTCH1, including D1642H, have been shown to be poor prognostic markers in lung cancer.",,9,139399219.0,139399219.0,C,G,ENST00000277541.6,75.0,GRCh37,,,,,missense_variant,"ENST00000277541.6:c.4924G>C,NC_000009.11:g.139399219C>G,NM_017617.4:c.4924G>C,NP_060087.3:p.Asp1642His",2018-11-30 14:43:02 UTC,20.0,CA16602788,376345,ASP1642HIS,,,
113,113,https://civic.genome.wustl.edu/links/variants/136,NOTCH1,4851,R2327W,"Activating mutations in NOTCH1, including R2327W, have been shown to be poor prognostic markers in lung cancer.",,9,139391212.0,139391212.0,G,A,ENST00000277541.6,75.0,GRCh37,,,,,missense_variant,"NM_017617.4:c.6979C>T,NP_060087.3:p.Arg2327Trp,NC_000009.11:g.139391212G>A",2018-11-30 14:43:02 UTC,20.0,CA5339772,376346,ARG2327TRP,,,
116,116,https://civic.genome.wustl.edu/links/variants/139,DDR2,4921,L63V,"Activating mutations in DDR2, including L63V, has been shown to be sensitive to dasatinib in cell lines.",,1,162724415.0,162724415.0,C,G,ENST00000367922.3,75.0,GRCh37,,,,,missense_variant,"NM_006182.2:c.187C>G,NP_006173.2:p.Leu63Val,ENST00000367922.3:c.187C>G,NC_000001.10:g.162724415C>G",2018-11-30 14:43:01 UTC,4.0,CA1217196,,LEU63VAL,,,
117,117,https://civic.genome.wustl.edu/links/variants/140,DDR2,4921,L239R,"Activating mutations in DDR2, including L239R, has been shown to be sensitive to dasatinib in cell lines.",,1,162729630.0,162729630.0,T,G,ENST00000367922.3,75.0,GRCh37,,,,,missense_variant,"ENST00000367922.3:c.716T>G,NC_000001.10:g.162729630T>G",2018-11-30 14:43:01 UTC,4.0,CA16602598,376141,LEU239ARG,,,
119,119,https://civic.genome.wustl.edu/links/variants/142,DDR2,4921,G505S,"Activating mutations in DDR2, including G505S, has been shown to be sensitive to dasatinib in cell lines.",,1,162741822.0,162741822.0,G,A,ENST00000367922.3,75.0,GRCh37,,,,,missense_variant,"NM_006182.2:c.1513G>A,NP_006173.2:p.Gly505Ser,ENST00000367922.3:c.1513G>A,NC_000001.10:g.162741822G>A",2018-11-30 14:43:02 UTC,4.0,CA1217584,282994,"GLY505SER,RS115169993",,,
121,121,https://civic.genome.wustl.edu/links/variants/144,DDR2,4921,G774V,"Activating mutations in DDR2, including G774V, has been shown to be sensitive to dasatinib in cell lines.",,1,162748407.0,162748407.0,G,T,ENST00000367922.3,75.0,GRCh37,,,,,missense_variant,"ENST00000367922.3:c.2321G>T,NC_000001.10:g.162748407G>T",2018-11-30 14:43:02 UTC,4.0,CA16602601,376144,GLY774VAL,,,
139,139,https://civic.genome.wustl.edu/links/variants/168,BTK,695,C481S,,,X,100611165.0,100611165.0,A,T,ENST00000308731.7,75.0,GRCh37,,,,,missense_variant,"ENST00000308731.7:c.1441T>A,NC_000023.10:g.100611165A>T,NM_000061.2:c.1441T>A,NP_000052.1:p.Cys481Ser",2018-11-30 14:43:09 UTC,40.0,CA16602659,376204,"CYS481SER,RS1057519826",,,
140,140,https://civic.genome.wustl.edu/links/variants/169,AKT1,207,Q79K,,,14,105243048.0,105243048.0,G,T,ENST00000407796.2,75.0,GRCh37,,,,,missense_variant,"NC_000014.8:g.105243048G>T,NM_001014432.1:c.235C>A,NP_001014432.1:p.Gln79Lys,ENST00000407796.2:c.235C>A",2018-11-30 14:43:10 UTC,14.0,CA16602625,376168,"Q17K,GLN79LYS",,,
165,165,https://civic.genome.wustl.edu/links/variants/196,FGFR3,2261,Y375C,,,4,1806099.0,1806099.0,A,G,ENST00000340107.4,75.0,GRCh37,,,,,missense_variant,"NC_000004.11:g.1806099A>G,NM_001163213.1:c.1124A>G,NP_000133.1:p.Tyr373Cys,ENST00000340107.4:c.1124A>G",2018-11-30 14:43:12 UTC,15.0,CA341413,16342,"TYR375CYS,Y373C",,,
170,170,https://civic.genome.wustl.edu/links/variants/201,KIT,3815,M541L,,,4,55593464.0,55593464.0,A,C,ENST00000288135.5,75.0,GRCh37,,,,,missense_variant,"NM_000222.2:c.1621A>C,NP_000213.1:p.Met541Leu,ENST00000288135.5:c.1621A>C,NC_000004.11:g.55593464A>C",2018-11-30 14:43:12 UTC,25.0,CA160347,41599,"MET541LEU,RS3822214",,,
201,201,https://civic.genome.wustl.edu/links/variants/244,ATM,472,N2875H,A missense mutation within the C-terminal phosphoinositide 3-kinase (PI3K) catalytic domain,,11,108218044.0,108218044.0,A,C,ENST00000278616.4,75.0,GRCh37,,,,,missense_variant,"ENST00000278616.4:c.8623A>C,NC_000011.9:g.108218044A>C,NM_000051.3:c.8623A>C,NP_000042.3:p.Asn2875His",2018-11-30 14:43:14 UTC,7.5,CA16602795,376353,"ASN2875HIS,RS1057519869",,,
214,214,https://civic.genome.wustl.edu/links/variants/258,MTHFR,4524,A222V,,,1,11856378.0,11856378.0,G,A,ENST00000376592.1,75.0,GRCh37,,,,,missense_variant,"NM_005957.4:c.665C>T,NP_005948.3:p.Ala222Val,ENST00000376592.1:c.665G>A,NC_000001.10:g.11856378G>A",2018-11-30 14:43:36 UTC,55.0,CA170990,3520,"RS1801133,C677T,ALA222VAL",,,
216,216,https://civic.genome.wustl.edu/links/variants/260,ABCG2,9429,Q141K,,,4,89052323.0,89052323.0,G,T,ENST00000237612.3,75.0,GRCh37,,,,,missense_variant,NC_000004.11:g.89052323G>T,2018-11-30 14:43:22 UTC,15.0,CA129179,30389,GLN141LYS,,,
243,243,https://civic.genome.wustl.edu/links/variants/288,BRAF,673,L597R,,Other V600's,7,140453145.0,140453145.0,A,C,ENST00000288602.6,75.0,GRCh37,,,,,missense_variant,"NM_004333.4:c.1790T>G,NP_004324.2:p.Leu597Arg,NC_000007.13:g.140453145A>C,ENST00000288602.6:c.1790T>G",2018-11-30 14:45:06 UTC,12.0,CA123649,13968,"LEU597ARG,RS121913366",,,
276,276,https://civic.genome.wustl.edu/links/variants/322,KRAS,3845,A146V,,,12,25378561.0,25378561.0,G,A,ENST00000256078.4,75.0,GRCh37,,,,,missense_variant,"ENST00000256078.4:c.437C>T,NC_000012.11:g.25378561G>A,NP_004976.2:p.Ala146Val,NM_004985.4:c.437C>T",2018-11-30 14:42:56 UTC,8.0,CA16602440,375962,"ALA146VAL,RS1057519725",,,
305,305,https://civic.genome.wustl.edu/links/variants/351,SETBP1,26040,G870S,,,18,42531913.0,42531913.0,G,A,ENST00000282030.5,75.0,GRCh37,,,,,missense_variant,"NM_015559.2:c.2608G>A,NP_056374.2:p.Gly870Ser,ENST00000282030.5:c.2608G>A,NC_000018.9:g.42531913G>A",2018-11-30 14:43:10 UTC,3.0,CA114719,1035,"GLY870SER,RS267607040",,,
320,320,https://civic.genome.wustl.edu/links/variants/367,RAC1,5879,P29S,,,7,6426892.0,6426892.0,C,T,ENST00000356142.4,75.0,GRCh37,,,,,missense_variant,"ENST00000356142.4:c.85C>T,NC_000007.13:g.6426892C>T",2018-11-30 14:42:56 UTC,4.0,CA16602801,376362,PRO29SER,,,
355,355,https://civic.genome.wustl.edu/links/variants/402,NQO1,1728,P187S,,,16,69745145.0,69745145.0,G,A,ENST00000320623.5,75.0,GRCh37,,,,,missense_variant,"NM_000903.2:c.559C>T,NP_000894.1:p.Pro187Ser,NC_000016.9:g.69745145G>A",2018-11-30 14:43:10 UTC,2.0,CA126904,16809,PRO187SER,,,
368,368,https://civic.genome.wustl.edu/links/variants/415,EGFR,1956,C797S,,,7,55249091.0,55249091.0,T,A,ENST00000275493.2,75.0,GRCh37,,,,,missense_variant,"ENST00000275493.2:c.2389T>A,NC_000007.13:g.55249091T>A,NM_005228.4:c.2389T>A,NP_005219.2:p.Cys797Ser",2018-11-30 14:43:20 UTC,17.5,CA16602785,376342,"CYS797SER,RS1057519861",,,
372,372,https://civic.genome.wustl.edu/links/variants/420,IDH1,3417,R132H,"IDH1 R132 mutations have been observed in a number of cancer types, and appear to behave quite differently in different environments. In myelodysplastic syndromes and acute myeloid leukemia (AML), IDH1 R132 mutations have been shown to be associated with worse outcome and shorter overall survival. They have also been linked to cytogenetically normal AML, an intermediate risk subtype of the disease. However, in glioblastoma and astrocytoma, patients with IDH1 mutations have shown better overall survival than patients with wild-type IDH1. Also in contrast to AML, in glioblastoma, IDH1 mutations have been associated with the specific cytogenetic abnormalities, 1p and 19q deletions.",,2,209113112.0,209113112.0,C,T,ENST00000415913.1,75.0,GRCh37,,,,,missense_variant,"NM_001282386.1:c.395G>A,NP_005887.2:p.Arg132His,NC_000002.11:g.209113112C>T,ENST00000415913.1:c.395G>A",2018-11-30 14:43:24 UTC,9.0,CA170874,156444,"ARG132HIS,RS121913500",,,
377,377,https://civic.genome.wustl.edu/links/variants/425,KRAS,3845,G12V,KRAS mutations are the most common mutations in pancreatic cancer occurring in > 90% of cases. Of these the G12D activating mutation is the most prevalent and results in a loss of GTPase activity which in turn leads to a constitutively active form of KRAS. This is enough to cause pre-cancerous pancreatic intraepithelial lesions,,12,25398284.0,25398284.0,C,A,ENST00000256078.4,75.0,GRCh37,,,,,missense_variant,"NM_004985.4:c.35G>T,NP_004976.2:p.Gly12Val,NC_000012.11:g.25398284C>A,ENST00000256078.4:c.35G>T",2018-11-30 14:45:24 UTC,43.0,CA122540,12583,"GLY12VAL,RS121913529",,,
379,379,https://civic.genome.wustl.edu/links/variants/427,NRAS,4893,Q61K,,,1,115256530.0,115256530.0,G,T,ENST00000369535.4,75.0,GRCh37,,,,,missense_variant,"NM_002524.4:c.181C>A,NP_002515.1:p.Gln61Lys,NC_000001.10:g.115256530G>T,ENST00000369535.4:c.181C>A",2018-11-30 14:43:22 UTC,12.0,CA151263,73058,"GLN61LYS,RS121913254",,,
394,394,https://civic.genome.wustl.edu/links/variants/443,EGFR,1956,G465R,,ECD MUTATION,7,55227926.0,55227926.0,G,A,ENST00000275493.2,75.0,GRCh37,,,,,missense_variant,"ENST00000275493.2:c.1393G>A,NC_000007.13:g.55227926G>A",2018-11-30 14:43:23 UTC,20.0,CA367579504,NONE FOUND,GLY465ARG,,,
402,402,https://civic.genome.wustl.edu/links/variants/451,ABCB1,5243,S893A/T,Refer to  https://www.pharmgkb.org/rsid/rs2032582  for more information.,,7,87160618.0,87160618.0,A,C,ENST00000265724.3,75.0,GRCh37,,,,,missense_variant,NC_000007.13:g.87160618A>C,2018-11-30 14:42:57 UTC,15.0,CA179699,"166622,166619",RS2032582,,,
403,403,https://civic.genome.wustl.edu/links/variants/453,EGFR,1956,S492R,,ECD MUTATION,7,55228009.0,55228009.0,C,A,ENST00000275493.2,75.0,GRCh37,,,,,missense_variant,"ENST00000275493.2:c.1476C>A,NC_000007.13:g.55228009C>A,NP_005219.2:p.Ser492Arg,NM_005228.4:c.1476C>A",2018-11-30 14:43:01 UTC,23.0,CA16602784,376341,SER492ARG,,,
404,404,https://civic.genome.wustl.edu/links/variants/454,EGFR,1956,R451C,,,7,55227884.0,55227884.0,C,T,ENST00000275493.2,75.0,GRCh37,,,,,missense_variant,"ENST00000275493.2:c.1351C>T,NC_000007.13:g.55227884C>T,NM_001346898.1:c.1351C>T,NP_001333827.1:p.Arg451Cys",2018-11-30 14:42:58 UTC,2.0,CA158917074,NONE FOUND,"ARG451CYS,RS377567759",,,
405,405,https://civic.genome.wustl.edu/links/variants/455,EGFR,1956,K467T,,ECD MUTATION,7,55227933.0,55227933.0,A,C,ENST00000275493.2,75.0,GRCh37,,,,,missense_variant,"ENST00000275493.2:c.1400A>C,NC_000007.13:g.55227933A>C",2018-11-30 14:43:03 UTC,6.0,CA367579521,,LYS467THR,,,
406,406,https://civic.genome.wustl.edu/links/variants/456,FCGR2A,2212,H167R,,,1,161479745.0,161479745.0,A,G,ENST00000271450.6,75.0,GRCh37,,,,,missense_variant,"NM_001136219.1:c.500A>G,NP_001129691.1:p.His167Arg,ENST00000271450.6:c.500A>G,NC_000001.10:g.161479745A>G",2018-11-30 14:42:56 UTC,35.0,CA124361,14823,"RS1801274,H131R,H166R,HIS167ARG",,,
407,407,https://civic.genome.wustl.edu/links/variants/457,FCGR3A,2214,F212V,,,1,161514542.0,161514542.0,A,C,ENST00000367969.3,75.0,GRCh37,,,,,missense_variant,NC_000001.10:g.161514542A>C,2018-11-30 14:42:58 UTC,35.0,CA1211378,,"RS396991,V158F",,,
408,408,https://civic.genome.wustl.edu/links/variants/458,FCGR2B,2213,I232T,,,1,161643798.0,161643798.0,T,C,ENST00000358671.5,75.0,GRCh37,,,,,missense_variant,"NM_004001.4:c.695T>C,NP_003992.3:p.Ile232Thr,ENST00000358671.5:c.695T>C,NC_000001.10:g.161643798T>C",2018-11-30 14:42:58 UTC,20.0,CA117549,5467,"RS1050501,ILE232THR",,,
409,409,https://civic.genome.wustl.edu/links/variants/460,EGFR,1956,P753S,,,7,55242487.0,55242487.0,C,T,ENST00000275493.2,75.0,GRCh37,,,,,missense_variant,"ENST00000275493.2:c.2257C>T,NC_000007.13:g.55242487C>T,NM_005228.4:c.2257C>T,NP_005219.2:p.Pro753Ser",2018-11-30 14:43:03 UTC,7.5,CA4266020,376081,"PRO753SER,RS121913231",,,
412,412,https://civic.genome.wustl.edu/links/variants/463,PML,5371,PML-RARA L218P,L218P in the B2 domain of PML is one of the variants found in a patient with ATRA-resistant APL.,PML-RARa B2 Domain,15,74315219.0,74315219.0,T,C,ENST00000268058.3,75.0,GRCh37,,,,,missense_variant,NC_000015.9:g.74315219T>C,2018-11-30 14:43:09 UTC,7.5,CA393121927,NONE FOUND,,,,
416,416,https://civic.genome.wustl.edu/links/variants/467,KDR,3791,A1065T,,,4,55955969.0,55955969.0,C,T,ENST00000263923.4,75.0,GRCh37,,,,,missense_variant,"NM_002253.2:c.3193G>A,NP_002244.1:p.Ala1065Thr,ENST00000263923.4:c.3193G>A,NC_000004.11:g.55955969C>T",2018-11-30 14:43:16 UTC,3.0,CA2924178,NONE FOUND,"ALA1065THR,RS56302315",,,
419,419,https://civic.genome.wustl.edu/links/variants/470,MTOR,2475,F2108L,,,1,11187094.0,11187094.0,G,T,ENST00000361445.4,75.0,GRCh37,,,,,missense_variant,"ENST00000361445.4:c.6324C>A,NC_000001.10:g.11187094G>T",2018-11-30 14:43:23 UTC,16.5,CA338391533,NONE FOUND,PHE2108LEU,,,
428,428,https://civic.genome.wustl.edu/links/variants/480,DNMT3A,1788,P904L,,,2,25457176.0,25457176.0,G,A,ENST00000264709.3,75.0,GRCh37,,,,,missense_variant,NC_000002.11:g.25457176G>A,2018-11-30 14:43:07 UTC,0.0,CA1555464,,,,,
443,443,https://civic.genome.wustl.edu/links/variants/496,ERBB2,2064,L866M,This mutation was shown to be an activating mutation and conferred sensitivity to a combination of trastuzumab with neratinib or lapatinib in colorectal cancer patient-derived xenografts.,,17,37881404.0,37881404.0,C,A,ENST00000269571.5,75.0,GRCh37,,,,,missense_variant,"ENST00000269571.5:c.2596C>A,NC_000017.10:g.37881404C>A",2018-11-30 14:43:11 UTC,4.0,CA399304874,NONE FOUND,LEU866MET,,,
462,462,https://civic.genome.wustl.edu/links/variants/515,FGFR1,2260,N546K,,,8,38274849.0,38274849.0,G,T,ENST00000341462.5,75.0,GRCh37,,,,,missense_variant,"NM_023110.2:c.1638C>A,NP_075598.2:p.Asn546Lys,ENST00000341462.5:c.1638C>A,NC_000008.10:g.38274849G>T",2018-11-30 14:43:21 UTC,0.5,CA357830,224896,"ASN546LYS,RS779707422",,,
486,486,https://civic.genome.wustl.edu/links/variants/540,FLT3,2322,T227M,"FLT3 T227M (rs1933437) is a common polymorphism with a GMAF around .60 based on the Exome Aggregation Consortium (ExAC) data. Its role in cancer predisposition is still unknown, however it may be associated with the development of leukopenia in patients treated with sunitinib.",,13,28624294.0,28624294.0,G,A,ENST00000241453.7,75.0,GRCh37,,,,,"missense_variant,SNP","NM_004119.2:c.680C>T,NP_004110.2:p.Thr227Met,NC_000013.10:g.28624294G>A",2018-11-30 14:43:26 UTC,15.0,CA159846,134447,"RS1933437,THR227MET",,,
488,488,https://civic.genome.wustl.edu/links/variants/542,MTOR,2475,S2215Y,,,1,11184573.0,11184573.0,G,T,ENST00000361445.4,75.0,GRCh37,,,,,missense_variant,"ENST00000361445.4:c.6644C>A,NC_000001.10:g.11184573G>T,NM_004958.3:c.6644C>A,NP_004949.1:p.Ser2215Tyr",2018-11-30 14:43:11 UTC,2.0,CA16602587,376129,SER2215TYR,,,
490,490,https://civic.genome.wustl.edu/links/variants/544,MTOR,2475,E1799K,,,1,11190804.0,11190804.0,C,T,ENST00000361445.4,75.0,GRCh37,,,,,missense_variant,"NM_004958.3:c.5395G>A,NP_004949.1:p.Glu1799Lys,NC_000001.10:g.11190804C>T,ENST00000361445.4:c.5395G>A",2018-11-30 14:43:11 UTC,2.0,CA279594,217823,"GLU1799LYS,RS863225264",,,
502,502,https://civic.genome.wustl.edu/links/variants/556,CDK4,1019,R24C,,,12,58145431.0,58145431.0,G,A,ENST00000257904.6,75.0,GRCh37,,,,,missense_variant,"NM_000075.3:c.70C>T,NP_000066.1:p.Arg24Cys,ENST00000257904.6:c.70C>T,NC_000012.11:g.58145431G>A",2018-11-30 14:43:16 UTC,1.0,CA126982,16928,"ARG24CYS,RS11547328",,,
504,504,https://civic.genome.wustl.edu/links/variants/558,GNA11,2767,Q209,,,19,3118942.0,3118942.0,,,ENST00000078429.4,75.0,GRCh37,,,,,missense_variant,,2017-12-01 14:40:33 UTC,15.0,,376001,,,,
507,507,https://civic.genome.wustl.edu/links/variants/562,EGFR,1956,S768I,,,7,55249005.0,55249005.0,G,T,ENST00000275493.2,75.0,GRCh37,,,,,missense_variant,"ENST00000275493.2:c.2303G>T,NC_000007.13:g.55249005G>T,NM_005228.4:c.2303G>T,NP_005219.2:p.Ser768Ile",2018-11-30 14:43:21 UTC,17.5,CA135840,45251,"SER768ILE,RS121913465",,,
508,508,https://civic.genome.wustl.edu/links/variants/563,BRAF,673,V600K,,Other V600's,7,140453136.0,140453137.0,AC,TT,ENST00000288602.6,75.0,GRCh37,,,,,missense_variant,"ENST00000288602.6:c.1798_1799delinsAA,NC_000007.13:g.140453136_140453137delinsTT,NM_004333.4:c.1798_1799delGTinsAA,NP_004324.2:p.Val600Lys",2018-11-30 14:43:19 UTC,82.5,CA16602420,375941,"VAL600LYS,RS121913227","11,13",https://civic.genome.wustl.edu/links/assertions/11,
510,510,https://civic.genome.wustl.edu/links/variants/565,SF3B1,23451,K700E,,HEAT domain mutation,2,198266834.0,198266834.0,T,C,ENST00000335508.6,75.0,GRCh37,,,,,missense_variant,"NM_012433.3:c.2098A>G,NP_036565.2:p.Lys700Glu,ENST00000335508.6:c.2098A>G,NC_000002.11:g.198266834T>C",2018-11-30 14:43:27 UTC,2.0,CA2042597,376004,"LYS700GLU,RS559063155",,,
511,511,https://civic.genome.wustl.edu/links/variants/566,MAP2K7,5609,E116K,,,19,7975157.0,7975157.0,G,A,ENST00000397979.3,75.0,GRCh37,,,,,missense_variant,NC_000019.9:g.7975157G>A,2018-11-30 14:43:27 UTC,25.0,CA304968685,NONE FOUND,GLU116LYS,,,
526,526,https://civic.genome.wustl.edu/links/variants/582,BRAF,673,L597S,,,7,140453145.0,140453146.0,AG,GA,ENST00000288602.6,75.0,GRCh37,,,,,missense_variant,"NC_000007.13:g.140453145_140453146delinsGA,NM_004333.4:c.1789_1790delCTinsTC,NP_004324.2:p.Leu597Ser,ENST00000288602.6:c.1789_1790delCTinsTC",2018-11-30 14:43:28 UTC,9.5,CA16602421,375942,LEU597SER,,,
527,527,https://civic.genome.wustl.edu/links/variants/583,BRAF,673,L597Q,,,7,140453145.0,140453145.0,A,T,ENST00000288602.6,75.0,GRCh37,,,,,missense_variant,"NM_004333.4:c.1790T>A,NP_004324.2:p.Leu597Gln,NC_000007.13:g.140453145A>T,ENST00000288602.6:c.1790T>A",2018-11-30 14:43:28 UTC,14.5,CA16602257,76687,"LEU597GLN,RS121913366",,,
528,528,https://civic.genome.wustl.edu/links/variants/584,BRAF,673,K601E,,,7,140453134.0,140453134.0,T,C,ENST00000288602.6,75.0,GRCh37,,,,,missense_variant,"NM_004333.4:c.1801A>G,NP_004324.2:p.Lys601Glu,NC_000007.13:g.140453134T>C,ENST00000288602.6:c.1801A>G",2018-11-30 14:43:28 UTC,3.0,CA123645,13966,"LYS601GLU,RS121913364",,,
529,529,https://civic.genome.wustl.edu/links/variants/585,BRAF,673,L597V,,,7,140453146.0,140453146.0,G,C,ENST00000288602.6,75.0,GRCh37,,,,,missense_variant,"NM_004333.4:c.1789C>G,NP_004324.2:p.Leu597Val,NC_000007.13:g.140453146G>C,ENST00000288602.6:c.1789C>G",2018-11-30 14:43:28 UTC,7.5,CA123651,13969,"LEU597VAL,RS121913369",,,
551,551,https://civic.genome.wustl.edu/links/variants/609,MTOR,2475,M2327I,,,1,11177096.0,11177096.0,C,A,ENST00000361445.4,75.0,GRCh37,,,,,missense_variant,"ENST00000361445.4:c.6981G>T,NC_000001.10:g.11177096C>A",2018-11-30 14:43:30 UTC,7.0,CA338383476,NONE FOUND,MET2327ILE,,,
552,552,https://civic.genome.wustl.edu/links/variants/610,MTOR,2475,A2034V,,,1,11187796.0,11187796.0,G,A,ENST00000361445.4,75.0,GRCh37,,,,,missense_variant,"ENST00000361445.4:c.6101C>T,NC_000001.10:g.11187796G>A",2018-11-30 14:43:30 UTC,8.0,CA338393920,NONE FOUND,ALA2034VAL,,,
553,553,https://civic.genome.wustl.edu/links/variants/611,BRAF,673,D594G,This BRAF mutation has a markedly reduced kinase activity and leads to paradoxical MEK-pathway activation via CRAF binding.,,7,140453154.0,140453154.0,T,C,ENST00000288602.6,75.0,GRCh37,,,,,missense_variant,"NM_004333.4:c.1781A>G,NP_004324.2:p.Asp594Gly,NC_000007.13:g.140453154T>C,ENST00000288602.6:c.1781A>G",2018-11-30 14:45:29 UTC,23.5,CA123657,13972,"ASP594GLY,RS121913338",,,
554,554,https://civic.genome.wustl.edu/links/variants/612,FLT3,2322,D835H,,,13,28592642.0,28592642.0,C,G,ENST00000241453.7,75.0,GRCh37,,,,,missense_variant,"NM_004119.2:c.2503G>C,NP_004110.2:p.Asp835His,ENST00000241453.7:c.2503G>C,NC_000013.10:g.28592642C>G",2018-11-30 14:43:30 UTC,7.5,CA280208,16273,"ASP835HIS,RS121913488",,,
555,555,https://civic.genome.wustl.edu/links/variants/613,FLT3,2322,D835H/Y,,,13,28592642.0,28592642.0,C,G/A,ENST00000241453.7,75.0,GRCh37,,,,,missense_variant,"NM_004119.2:c.2503G>C,NP_004110.2:p.Asp835His,NM_004119.2:c.2503G>T,NP_004110.2:p.Asp835Tyr,ENST00000241453.7:c.2503G>C,ENST00000241453.7:c.2503G>T",2017-12-01 14:40:33 UTC,1.0,,"16276,16273","ASP835HIS,ASP835TYR",,,
568,568,https://civic.genome.wustl.edu/links/variants/628,FGFR3,2261,S249C,,,4,1803568.0,1803568.0,C,G,ENST00000340107.4,75.0,GRCh37,,,,,missense_variant,NC_000004.11:g.1803568C>G,2018-11-30 14:43:32 UTC,5.0,CA126380,16339,"SER249CYS,RS121913483",,,
589,589,https://civic.genome.wustl.edu/links/variants/649,MET,4233,D1228N,,,7,116423407.0,116423407.0,G,A,ENST00000397752.3,75.0,GRCh37,,,,,missense_variant,"NM_001127500.2:c.3736G>A,NP_001120972.1:p.Asp1246Asn,NC_000007.13:g.116423407G>A,ENST00000397752.3:c.3682G>A",2018-11-30 14:43:33 UTC,5.0,CA257000,13884,"D1246N,ASP1246ASN",,,
601,601,https://civic.genome.wustl.edu/links/variants/661,BRCA2,675,D3095E,,,13,32968854.0,32968854.0,C,A,ENST00000544455.1,75.0,GRCh37,,,,,missense_variant,"NM_000059.3:c.9285C>A,NP_000050.2:p.Asp3095Glu,ENST00000544455.1:c.9285C>A,NC_000013.10:g.32968854C>A",2018-11-30 14:43:34 UTC,2.5,CA10586089,252859,"ASP3095GLU,RS80359198",,,
617,617,https://civic.genome.wustl.edu/links/variants/692,ESR1,2099,S463P,,,6,152415537.0,152415537.0,T,C,ENST00000440973.1,75.0,GRCh37,,,,,missense_variant,"ENST00000440973.1:c.1387T>C,NC_000006.11:g.152415537T>C",2018-11-30 14:43:34 UTC,2.0,CA16602414,375934,SER463PRO,,,
619,619,https://civic.genome.wustl.edu/links/variants/694,BRAF,673,G596C,,,7,140453149.0,140453149.0,C,A,ENST00000288602.6,75.0,GRCh37,,,,,missense_variant,"NM_004333.4:c.1786G>T,NP_004324.2:p.Gly596Cys,NC_000007.13:g.140453149C>A,ENST00000288602.6:c.1786G>T",2018-11-30 14:43:35 UTC,0.0,CA135098,44814,"GLY596CYS,RS121913361",,,
626,626,https://civic.genome.wustl.edu/links/variants/701,ERBB3,2065,V104M,,,12,56478854.0,56478854.0,G,A,ENST00000267101.3,75.0,GRCh37,,,,,missense_variant,NC_000012.11:g.56478854G>A,2018-11-30 14:43:36 UTC,15.0,CA16602847,376410,VAL104MET,,,
627,627,https://civic.genome.wustl.edu/links/variants/702,ERBB3,2065,R103G,,,12,56478851.0,56478851.0,C,G,ENST00000267101.3,75.0,GRCh37,,,,,missense_variant,NC_000012.11:g.56478851C>G,2018-11-30 14:43:35 UTC,15.0,CA385279657,NONE FOUND,ARG103GLY,,,
628,628,https://civic.genome.wustl.edu/links/variants/703,ERBB3,2065,G284R,,,12,56481922.0,56481922.0,G,A,ENST00000267101.3,75.0,GRCh37,,,,,missense_variant,NC_000012.11:g.56481922G>A,2018-11-30 14:43:37 UTC,15.0,CA16602624,376167,GLY284ARG,,,
635,635,https://civic.genome.wustl.edu/links/variants/712,EGFR,1956,D761Y,,,7,55242511.0,55242511.0,G,T,ENST00000275493.2,75.0,GRCh37,,,,,missense_variant,"ENST00000275493.2:c.2281G>T,NM_005228.4:c.2281G>T,NP_005219.2:p.Asp761Tyr,NC_000007.13:g.55242511G>T",2018-11-30 14:43:37 UTC,7.5,CA135827,45244,"ASP761TYR,RS121913418",,,
637,637,https://civic.genome.wustl.edu/links/variants/714,TSC1,7248,R1062W,,,9,135771933.0,135771933.0,G,A,ENST00000298552.3,75.0,GRCh37,,,,,missense_variant,"NM_000368.3:c.3184C>T,NP_000359.1:p.Arg1062Trp,ENST00000298552.3:c.3184C>T,NC_000009.11:g.135771933G>A",2018-11-30 14:43:37 UTC,8.0,CA007223,49015,ARG1062TRP,,,
646,646,https://civic.genome.wustl.edu/links/variants/723,EGFR,1956,K757R,,,7,55242500.0,55242500.0,A,G,ENST00000275493.2,75.0,GRCh37,,,,,missense_variant,"ENST00000275493.2:c.2270A>G,NC_000007.13:g.55242500A>G",2018-11-30 14:45:08 UTC,7.5,CA4266023,NONE FOUND,,,,
666,666,https://civic.genome.wustl.edu/links/variants/743,MLH1,4292,T117M,,,3,37045935.0,37045935.0,C,T,ENST00000231790.2,75.0,GRCh37,,,,,missense_variant,"NM_000249.3:c.350C>T,NP_000240.1:p.Thr117Met,ENST00000231790.2:c.350C>T,NC_000003.11:g.37045935C>T",2018-11-30 14:43:38 UTC,0.5,CA009872,17094,"THR117MET,RS63750781",,,
670,670,https://civic.genome.wustl.edu/links/variants/747,MLH1,4292,M1L,,,3,37035039.0,37035039.0,A,T,ENST00000231790.2,75.0,GRCh37,,,,,missense_variant,"ENST00000231790.2:c.1A>T,NC_000003.11:g.37035039A>T",2018-11-30 14:43:39 UTC,0.5,CA352059785,NONE FOUND,MET1LEU,,,
672,672,https://civic.genome.wustl.edu/links/variants/749,MLH1,4292,R265G,,,3,37058999.0,37058999.0,C,G,ENST00000231790.2,75.0,GRCh37,,,,,missense_variant,"ENST00000231790.2:c.793C>G,NC_000003.11:g.37058999C>G",2018-11-30 14:43:44 UTC,0.5,CA352045752,NONE FOUND,ARG265GLY,,,
692,692,https://civic.genome.wustl.edu/links/variants/769,MLH1,4292,M490T,,,3,37070334.0,37070334.0,T,C,ENST00000231790.2,75.0,GRCh37,,,,,missense_variant,"ENST00000231790.2:c.1469T>C,NC_000003.11:g.37070334T>C",2018-11-30 14:43:41 UTC,0.25,CA352056416,NONE FOUND,MET490THR,,,
695,695,https://civic.genome.wustl.edu/links/variants/772,HOXB13,10481,G84E,,,17,46805705.0,46805705.0,C,T,ENST00000290295.7,75.0,GRCh37,,,,,missense_variant,"NC_000017.10:g.46805705C>T,NM_006361.5:c.251G>A,NP_006352.2:p.Gly84Glu,ENST00000290295.7:c.251G>A",2018-11-30 14:43:36 UTC,40.0,CA288225,128031,"RS138213197,GLY84GLU",,,
696,696,https://civic.genome.wustl.edu/links/variants/773,MSH2,4436,E483G,,,2,47690231.0,47690231.0,A,G,ENST00000233146.2,75.0,GRCh37,,,,,missense_variant,"NC_000002.11:g.47690231A>G,ENST00000233146.2:c.1448A>G",2018-11-30 14:43:41 UTC,0.5,CA346726930,NONE FOUND,GLU483GLY,,,
698,698,https://civic.genome.wustl.edu/links/variants/775,MSH6,2956,V352I,,,2,48026176.0,48026176.0,G,A,ENST00000234420.5,75.0,GRCh37,,,,,missense_variant,"NM_000179.2:c.1054G>A,NP_000170.1:p.Val352Ile,ENST00000234420.5:c.1054G>A,NC_000002.11:g.48026176G>A",2018-11-30 14:43:41 UTC,0.5,CA007915,182617,"VAL352ILE,RS730881787",,,
701,701,https://civic.genome.wustl.edu/links/variants/778,SLCO1B1,10599,N130D,,,12,21329738.0,21329738.0,A,G,ENST00000256958.2,75.0,GRCh37,,,,,missense_variant,NC_000012.11:g.21329738A>G,2018-11-30 14:43:33 UTC,15.0,CA6476674,259983,"ASN130ASP,RS2306283",,,
726,726,https://civic.genome.wustl.edu/links/variants/807,RUNX1,861,A107P,,,21,36252962.0,36252962.0,C,G,ENST00000344691.4,75.0,GRCh37,,,,,missense_variant,"NM_001754.4:c.400G>C,NP_001745.2:p.Ala134Pro,NC_000021.8:g.36252962C>G,ENST00000344691.4:c.400G>C",2018-11-30 14:43:42 UTC,12.5,CA248623,14468,"A134P,ALA134PRO,RS74315451",,,
732,732,https://civic.genome.wustl.edu/links/variants/813,ETV6,2120,P214L,,,12,12022535.0,12022535.0,C,T,ENST00000396373.4,75.0,GRCh37,,,,,missense_variant,,2018-11-30 14:43:45 UTC,0.0,CA175031,,,,,
738,738,https://civic.genome.wustl.edu/links/variants/820,VHL,7428,A149S (c.445G>T),,,3,10188302.0,10188302.0,G,T,ENST00000256474.2,75.0,GRCh37,,,,,missense_variant,"NP_000542.1:p.Ala149Ser,NM_000551.2:c.445G>T,ENST00000256474.2:c.445G>T,NC_000003.11:g.10188302G>T",2018-11-30 14:43:43 UTC,17.5,CA020355,127829,"ALA149SER,C.445G>T,RS587780077",,,
740,740,https://civic.genome.wustl.edu/links/variants/822,JAK1,3716,S703I,,,1,65311203.0,65311203.0,C,A,ENST00000342505.4,75.0,GRCh37,,,,,missense_variant,"ENST00000342505.4:c.2108G>T,NC_000001.10:g.65311203C>A",2018-11-30 14:43:46 UTC,4.0,CA340667333,NONE FOUND,SER703ILE,,,
774,774,https://civic.genome.wustl.edu/links/variants/862,PDGFRA,5156,P577S,,,4,55141083.0,55141083.0,C,T,ENST00000257290.5,75.0,GRCh37,,,,,missense_variant,"NM_006206.4:c.1729C>T,NP_006197.1:p.Pro577Ser,NC_000004.11:g.55141083C>T,ENST00000257290.5:c.1729C>T",2018-11-30 14:43:50 UTC,3.0,CA16602636,376181,"PRO577SER,RS1057519811",,,
777,777,https://civic.genome.wustl.edu/links/variants/865,PDGFRA,5156,G853D,,,4,55152126.0,55152126.0,G,A,ENST00000257290.5,75.0,GRCh37,,,,,missense_variant,"NM_006206.4:c.2558G>A,NP_006197.1:p.Gly853Asp,NC_000004.11:g.55152126G>A,ENST00000257290.5:c.2558G>A",2018-11-30 14:43:50 UTC,3.0,CA16602640,376185,"GLY853ASP,RS763576329",,,
782,782,https://civic.genome.wustl.edu/links/variants/870,BTK,695,T316A,,,X,100613633.0,100613633.0,T,C,ENST00000308731.7,75.0,GRCh37,,,,,missense_variant,"ENST00000308731.7:c.946T>C,NM_000061.2:c.946T>C,NC_000023.10:g.100613633T>C",2018-11-30 14:43:50 UTC,10.0,CA413928923,NONE FOUND,THR316ALA,,,
783,783,https://civic.genome.wustl.edu/links/variants/871,ERBB2,2064,T862A,,,17,37881392.0,37881392.0,A,G,ENST00000269571.5,75.0,GRCh37,,,,,missense_variant,"ENST00000269571.5:c.2584A>G,NC_000017.10:g.37881392A>G",2018-11-30 14:43:51 UTC,3.0,CA399304738,NONE FOUND,THR862ALA,,,
792,792,https://civic.genome.wustl.edu/links/variants/880,IDH1,3417,R132L,,,2,209113112.0,209113112.0,C,A,ENST00000415913.1,75.0,GRCh37,,,,,missense_variant,"NM_001282386.1:c.395G>T,NP_001269315.1:p.Arg132Leu,NC_000002.11:g.209113112C>A,ENST00000415913.1:c.395G>T",2018-11-30 14:43:51 UTC,10.0,CA16602372,375889,"RS121913500,ARG132LEU",,,
795,795,https://civic.genome.wustl.edu/links/variants/883,PIK3CA,5290,E545G,,,3,178936092.0,178936092.0,A,G,ENST00000263967.3,75.0,GRCh37,,,,,missense_variant,"NM_006218.3:c.1634A>G,NP_006209.2:p.Glu545Gly,NC_000003.11:g.178936092A>G,ENST00000263967.3:c.1634A>G",2018-11-30 14:44:09 UTC,2.0,CA123336,13656,"RS121913274,GLU545GLY",,,
796,796,https://civic.genome.wustl.edu/links/variants/884,PIK3CA,5290,E545V,,,3,178936092.0,178936092.0,A,T,ENST00000263967.3,75.0,GRCh37,,,,,missense_variant,"NM_006218.3:c.1634A>T,NP_006209.2:p.Glu545Val,NC_000003.11:g.178936092A>T,ENST00000263967.3:c.1634A>T",2018-11-30 14:43:51 UTC,0.0,CA16602380,375897,"RS121913274,GLU545VAL",,,
797,797,https://civic.genome.wustl.edu/links/variants/885,PIK3CA,5290,Q546K,,,3,178936094.0,178936094.0,C,A,ENST00000263967.3,75.0,GRCh37,,,,,missense_variant,"NM_006218.3:c.1636C>A,NP_006209.2:p.Gln546Lys,NC_000003.11:g.178936094C>A,ENST00000263967.3:c.1636C>A",2018-11-30 14:43:51 UTC,0.0,CA123338,13657,"RS121913286,GLN546LYS",,,
798,798,https://civic.genome.wustl.edu/links/variants/886,PIK3CA,5290,Q546E,,,3,178936094.0,178936094.0,C,G,ENST00000263967.3,75.0,GRCh37,,,,,missense_variant,"NM_006218.3:c.1636C>G,NP_006209.2:p.Gln546Glu,NC_000003.11:g.178936094C>G,ENST00000263967.3:c.1636C>G",2018-11-30 14:44:07 UTC,0.0,CA123331,13654,"RS121913286,GLN546GLU",,,
801,801,https://civic.genome.wustl.edu/links/variants/892,ABL1,25,BCR-ABL F359V,,,9,133748414.0,133748414.0,T,G,ENST00000318560.5,75.0,GRCh37,,,,,missense_variant,"NM_005157.5:c.1075T>G,NP_005148.2:p.Phe359Val,NC_000009.11:g.133748414T>G,ENST00000318560.5:c.1075T>G",2019-01-31 10:29:44 UTC,44.5,CA16602557,376096,"RS121913452,BCR-ABL F378V,BCR-ABL PHE359VAL",,,
805,805,https://civic.genome.wustl.edu/links/variants/897,NRAS,4893,G12C,,,1,115258748.0,115258748.0,C,A,ENST00000369535.4,75.0,GRCh37,,,,,missense_variant,"NM_002524.4:c.34G>T,NP_002515.1:p.Gly12Cys,NC_000001.10:g.115258748C>A,ENST00000369535.4:c.34G>T",2018-11-30 14:43:49 UTC,0.0,CA297020,40468,"RS121913250,GLY12CYS",,,
808,808,https://civic.genome.wustl.edu/links/variants/902,ATM,472,L2890V,,,11,108218089.0,108218089.0,C,G,ENST00000278616.4,75.0,GRCh37,,,,,missense_variant,"NM_000051.3:c.8668C>G,NP_000042.3:p.Leu2890Val,NC_000011.9:g.108218089C>G,ENST00000278616.4:c.8668C>G",2018-11-30 14:43:52 UTC,0.0,CA287027,127462,"LEU2890VAL,RS587779874",,,
809,809,https://civic.genome.wustl.edu/links/variants/903,ATM,472,R3008C,,,11,108236086.0,108236086.0,C,T,ENST00000278616.4,75.0,GRCh37,,,,,missense_variant,NC_000011.9:g.108236086C>T,2018-11-30 14:43:59 UTC,0.0,CA294307,,,,,
816,816,https://civic.genome.wustl.edu/links/variants/910,KRAS,3845,Q61K,,,12,25380277.0,25380277.0,G,T,ENST00000256078.4,75.0,GRCh37,,,,,missense_variant,"NM_004985.4:c.181C>A,NP_004976.2:p.Gln61Lys,NC_000012.11:g.25380277G>T,ENST00000256078.4:c.181C>A",2018-11-30 14:43:49 UTC,0.0,CA180750,177777,"RS121913238,GLN61LYS",,,
817,817,https://civic.genome.wustl.edu/links/variants/911,KRAS,3845,G13C,,,12,25398282.0,25398282.0,C,A,ENST00000256078.4,75.0,GRCh37,,,,,missense_variant,"NM_004985.4:c.37G>T,NP_004976.2:p.Gly13Cys,NC_000012.11:g.25398282C>A,ENST00000256078.4:c.37G>T",2018-11-30 14:43:19 UTC,0.0,CA135570,45123,"RS121913535,GLY13CYS",,,
818,818,https://civic.genome.wustl.edu/links/variants/913,KRAS,3845,G12S,,,12,25398285.0,25398285.0,C,T,ENST00000256078.4,75.0,GRCh37,,,,,missense_variant,"NM_004985.4:c.34G>A,NP_004976.2:p.Gly12Ser,NC_000012.11:g.25398285C>T,ENST00000256078.4:c.34G>A",2018-11-30 14:44:09 UTC,23.5,CA135565,12584,"RS121913530,GLY12SER",,,
819,819,https://civic.genome.wustl.edu/links/variants/918,TP53,7157,R273L,,,17,7577120.0,7577120.0,C,A,ENST00000269305.4,75.0,GRCh37,,,,,missense_variant,"NM_000546.5:c.818G>T,NP_000537.3:p.Arg273Leu,NC_000017.10:g.7577120C>A,ENST00000269305.4:c.818G>T",2018-11-30 14:45:06 UTC,0.0,CA001530,376655,"RS28934576,ARG273LEU",,,
822,822,https://civic.genome.wustl.edu/links/variants/927,IDH1,3417,R132G,,,2,209113113.0,209113113.0,G,C,ENST00000415913.1,75.0,GRCh37,,,,,missense_variant,"NM_001282386.1:c.394C>G,NP_001269315.1:p.Arg132Gly,NC_000002.11:g.209113113G>C,ENST00000415913.1:c.394C>G",2018-11-30 14:43:53 UTC,0.0,CA16602375,375892,"RS121913499,ARG132GLY",,,
825,825,https://civic.genome.wustl.edu/links/variants/931,PIK3CA,5290,C420R,,,3,178927980.0,178927980.0,T,C,ENST00000263967.3,75.0,GRCh37,,,,,missense_variant,"NM_006218.3:c.1258T>C,NP_006209.2:p.Cys420Arg,NC_000003.11:g.178927980T>C,ENST00000263967.3:c.1258T>C",2018-11-30 14:44:03 UTC,0.0,CA180900,31945,"RS121913272,CYS420ARG",,,
826,826,https://civic.genome.wustl.edu/links/variants/933,PIK3CA,5290,E542Q,,,3,178936082.0,178936082.0,G,C,ENST00000263967.3,75.0,GRCh37,,,,,missense_variant,"NM_006218.3:c.1624G>C,NP_006209.2:p.Glu542Gln,NC_000003.11:g.178936082G>C,ENST00000263967.3:c.1624G>C",2018-11-30 14:43:53 UTC,0.0,CA16602697,376244,"RS121913273,GLU542GLN",,,
827,827,https://civic.genome.wustl.edu/links/variants/934,PIK3CA,5290,E545D,,,3,178936093.0,178936093.0,G,C,ENST00000263967.3,75.0,GRCh37,,,,,missense_variant,"NM_006218.3:c.1635G>C,NP_006209.2:p.Glu545Asp,NC_000003.11:g.178936093G>C,ENST00000263967.3:c.1635G>C",2018-11-30 14:44:07 UTC,0.0,CA16602698,376245,"RS121913275,GLU545ASP",,,
828,828,https://civic.genome.wustl.edu/links/variants/935,PIK3CA,5290,Y1021C,,,3,178952007.0,178952007.0,A,G,ENST00000263967.3,75.0,GRCh37,,,,,missense_variant,"NM_006218.3:c.3062A>G,NP_006209.2:p.Tyr1021Cys,NC_000003.11:g.178952007A>G,ENST00000263967.3:c.3062A>G",2018-11-30 14:43:23 UTC,0.0,CA16602699,376246,"RS121913288,TYR1021CYS",,,
830,830,https://civic.genome.wustl.edu/links/variants/938,PIK3CA,5290,H1047Y,,,3,178952084.0,178952084.0,C,T,ENST00000263967.3,75.0,GRCh37,,,,,missense_variant,"NM_006218.3:c.3139C>T,NP_006209.2:p.His1047Tyr,NC_000003.11:g.178952084C>T,ENST00000263967.3:c.3139C>T",2018-11-30 14:43:55 UTC,0.0,CA130471,39705,"RS121913281,HIS1047TYR",,,
862,862,https://civic.genome.wustl.edu/links/variants/975,KIT,3815,Q575L,,,4,55593658.0,55593658.0,A,T,ENST00000288135.5,75.0,GRCh37,,,,,missense_variant,"ENST00000288135.5:c.1724A>T,NC_000004.11:g.55593658A>T,NM_000222.2:c.1724A>T,NP_000213.1:p.Gln575Leu",2019-02-26 18:22:35 UTC,5.0,CA356907571,NONE FOUND,GLN575LEU,,,
863,863,https://civic.genome.wustl.edu/links/variants/976,KIT,3815,P577L,,,4,55593664.0,55593664.0,C,T,ENST00000288135.5,75.0,GRCh37,,,,,missense_variant,"ENST00000288135.5:c.1730C>T,NC_000004.11:g.55593664C>T,NM_000222.2:c.1730C>T,NP_000213.1:p.Pro577Leu",2018-11-30 14:44:07 UTC,0.0,CA356907583,NONE FOUND,PRO577LEU,,,
865,865,https://civic.genome.wustl.edu/links/variants/978,KIT,3815,K642E,,,4,55594221.0,55594221.0,A,G,ENST00000288135.5,75.0,GRCh37,,,,,missense_variant,"NM_000222.2:c.1924A>G,NP_000213.1:p.Lys642Glu,NC_000004.11:g.55594221A>G,ENST00000288135.5:c.1924A>G",2019-02-23 01:34:14 UTC,7.0,CA123547,13866,"RS121913512,LYS642GLU",,,
867,867,https://civic.genome.wustl.edu/links/variants/980,KIT,3815,S692L,,,4,55595585.0,55595585.0,C,T,ENST00000288135.5,75.0,GRCh37,,,,,missense_variant,"ENST00000288135.5:c.2075C>T,NP_000213.1:p.Ser692Leu,NC_000004.11:g.55595585C>T,NM_000222.2:c.2075C>T",2018-11-30 14:43:00 UTC,0.0,CA2923640,NONE FOUND,"SER692LEU,RS757733297",,,
868,868,https://civic.genome.wustl.edu/links/variants/981,KIT,3815,Q694K,,,4,55595590.0,55595590.0,C,A,ENST00000288135.5,75.0,GRCh37,,,,,missense_variant,"ENST00000288135.5:c.2080C>A,NC_000004.11:g.55595590C>A,NM_000222.2:c.2080C>A,NP_000213.1:p.Gln694Lys",2018-11-30 14:43:54 UTC,0.0,CA356909653,NONE FOUND,GLN694LYS,,,
870,870,https://civic.genome.wustl.edu/links/variants/984,KIT,3815,D816Y,,,4,55599320.0,55599320.0,G,T,ENST00000288135.5,75.0,GRCh37,,,,,missense_variant,"NM_000222.2:c.2446G>T,NP_000213.1:p.Asp816Tyr,NC_000004.11:g.55599320G>T,ENST00000288135.5:c.2446G>T",2019-03-13 00:00:03 UTC,0.0,CA280196,13860,RS121913506,,,
871,871,https://civic.genome.wustl.edu/links/variants/986,KIT,3815,D820Y,,,4,55599332.0,55599332.0,G,T,ENST00000288135.5,75.0,GRCh37,,,,,missense_variant,"NM_000222.2:c.2458G>T,NP_000213.1:p.Asp820Tyr,NC_000004.11:g.55599332G>T,ENST00000288135.5:c.2458G>T",2019-03-21 20:40:04 UTC,14.5,CA16602408,375928,"ASP820TYR,RS1057519710",,,
872,872,https://civic.genome.wustl.edu/links/variants/987,KIT,3815,N822H,,,4,55599338.0,55599338.0,A,C,,,GRCh37,,,,,missense_variant,,2019-02-26 00:00:03 UTC,0.0,CA356911968,,,,,
873,873,https://civic.genome.wustl.edu/links/variants/989,KIT,3815,Y823D,,,4,55599341.0,55599341.0,T,G,ENST00000288135.5,75.0,GRCh37,,,,,missense_variant,"NM_000222.2:c.2467T>G,NP_000213.1:p.Tyr823Asp,NC_000004.11:g.55599341T>G,ENST00000288135.5:c.2467T>G",2018-11-30 14:45:05 UTC,7.5,CA16602561,376101,"TYR823ASP,RS1057519761",,,
874,874,https://civic.genome.wustl.edu/links/variants/990,KIT,3815,A829P,,,4,55602664.0,55602664.0,G,C,,,GRCh37,,,,,missense_variant,,2019-03-13 00:00:03 UTC,0.0,CA16602413,,,,,
877,877,https://civic.genome.wustl.edu/links/variants/993,BRAF,673,G469E,The BRAF G469E mutation has a markedly reduced kinase activity and thus activates the MEK pathway through CRAF binding.,,7,140481402.0,140481402.0,C,T,,,GRCh37,,,,,missense_variant,,2019-03-22 01:59:05 UTC,6.0,CA279970,,RS121913355,,,
880,880,https://civic.genome.wustl.edu/links/variants/996,EGFR,1956,A289V,,,7,55221822.0,55221822.0,C,T,ENST00000275493.2,75.0,GRCh37,,,,,missense_variant,"NM_005228.4:c.866C>T,NP_005219.2:p.Ala289Val,NC_000007.13:g.55221822C>T,ENST00000275493.2:c.866C>T",2018-11-30 14:43:57 UTC,3.0,CA16602664,376209,"RS149840192,ALA289VAL",,,
905,905,https://civic.genome.wustl.edu/links/variants/1027,ABL1,25,BCR-ABL D276G,,,9,133747520.0,133747520.0,A,G,ENST00000318560.5,75.0,GRCh37,,,,,missense_variant,"ENST00000318560.5:c.827A>G,NP_005148.2:p.Asp276Gly,NM_005157.5:c.827A>G,NC_000009.11:g.133747520A>G",2018-11-30 14:44:00 UTC,16.0,CA200645023,NONE FOUND,"RS121913447,BCR-ABL ASP276GLY,BCR-ABL D295G,BCR-ABL1 D295G",,,
906,906,https://civic.genome.wustl.edu/links/variants/1029,ABL1,25,BCR-ABL M351T,,,9,133748391.0,133748391.0,T,C,ENST00000318560.5,75.0,GRCh37,,,,,missense_variant,"NM_005157.5:c.1052T>C,NP_005148.2:p.Met351Thr,NC_000009.11:g.133748391T>C,ENST00000318560.5:c.1052T>C",2019-01-31 10:20:40 UTC,38.0,CA122590,12629,"RS121913457,M370T,MET351THR,MET370THR,BCR-ABL1 M351T",,,
907,907,https://civic.genome.wustl.edu/links/variants/1030,ABL1,25,BCR-ABL H396R,,,9,133750356.0,133750356.0,A,G,ENST00000318560.5,75.0,GRCh37,,,,,missense_variant,"NM_005157.5:c.1187A>G,NP_005148.2:p.His396Arg,NC_000009.11:g.133750356A>G,ENST00000318560.5:c.1187A>G",2019-01-24 17:37:50 UTC,26.5,CA16602558,376097,"RS121913454,BCR-ABL HIS415ARG,BCR-ABL HIS396ARG,BCR-ABL H415R",,,
918,918,https://civic.genome.wustl.edu/links/variants/1104,KRAS,3845,Q61E,,,12,25380277.0,25380277.0,G,C,ENST00000256078.4,75.0,GRCh37,,,,,missense_variant,"NM_004985.4:c.181C>G,NP_004976.2:p.Gln61Glu,NC_000012.11:g.25380277G>C,ENST00000256078.4:c.181C>G",2018-11-30 14:44:02 UTC,0.0,CA16602770,376324,"RS121913238,GLN61GLU",,,
922,922,https://civic.genome.wustl.edu/links/variants/1108,TP53,7157,R282L,,,17,7577093.0,7577093.0,C,A,ENST00000269305.4,75.0,GRCh37,,,,,missense_variant,"NM_000546.5:c.845G>T,NP_000537.3:p.Arg282Leu,NC_000017.10:g.7577093C>A,ENST00000269305.4:c.845G>T",2018-11-30 14:44:04 UTC,0.0,CA000456,182938,"ARG282LEU,R150L,R243L,RS730882008",,,
928,928,https://civic.genome.wustl.edu/links/variants/1127,NOTCH1,4851,F1592S,,,9,139399368.0,139399368.0,A,G,ENST00000277541.6,75.0,GRCh37,,,,,missense_variant,"ENST00000277541.6:c.4775T>C,NC_000009.11:g.139399368A>G",2018-11-30 14:44:04 UTC,0.0,CA375645052,NONE FOUND,PHE1592SER,,,
941,941,https://civic.genome.wustl.edu/links/variants/1158,ATM,472,F1025L,,,11,108142131.0,108142131.0,T,G,ENST00000278616.4,75.0,GRCh37,,,,,missense_variant,"ENST00000278616.4:c.3075T>G,NC_000011.9:g.108142131T>G,NM_000051.3:c.3075T>G,NP_000042.3:p.Phe1025Leu",2018-11-30 14:44:16 UTC,0.0,CA382547708,NONE FOUND,PHE1025LEU,,,
943,943,https://civic.genome.wustl.edu/links/variants/1160,ATM,472,D1930V,,,11,108180913.0,108180913.0,A,T,ENST00000278616.4,75.0,GRCh37,,,,,missense_variant,"ENST00000278616.4:c.5789A>T,NC_000011.9:g.108180913A>T,NM_000051.3:c.5789A>T,NP_000042.3:p.Asp1930Val",2018-11-30 14:44:08 UTC,0.0,CA382548326,NONE FOUND,"M72L,ASP1930VAL,MET72LEU",,,
946,946,https://civic.genome.wustl.edu/links/variants/1163,ATM,472,L2427P,,,11,108199938.0,108199938.0,T,C,ENST00000278616.4,75.0,GRCh37,,,,,missense_variant,"ENST00000278616.4:c.7280T>C,NC_000011.9:g.108199938T>C,NM_000051.3:c.7280T>C,NP_000042.3:p.Leu2427Pro",2018-11-30 14:44:08 UTC,0.0,CA382559785,NONE FOUND,LEU2427PRO,,,
971,971,https://civic.genome.wustl.edu/links/variants/1230,ABL1,25,L384M,,,9,133750319.0,133750319.0,C,A,ENST00000318560.5,75.0,GRCh37,,,,,missense_variant,"ENST00000318560.5:c.1150C>A,NC_000009.11:g.133750319C>A,NM_005157.5:c.1150C>A,NP_005148.2:p.Leu384Met",2018-11-30 14:44:10 UTC,3.5,CA375249885,NONE FOUND,"L403M,LEU403MET,LEU384MET",,,
972,972,https://civic.genome.wustl.edu/links/variants/1231,ABL1,25,BCR-ABL V299L,,,9,133747588.0,133747588.0,G,C,ENST00000318560.5,75.0,GRCh37,,,,,missense_variant,"NM_005157.5:c.895G>C,NP_005148.2:p.Val299Leu,NC_000009.11:g.133747588G>C,ENST00000318560.5:c.895G>C",2019-01-24 17:37:07 UTC,20.0,CA16602575,376117,"BCR-ABL VAL299LEU,BCR-ABL V318L,RS1057519771",,,
983,983,https://civic.genome.wustl.edu/links/variants/1242,BRCA1,672,R1495M,,,17,41228505.0,41228505.0,C,A,ENST00000357654.3,75.0,GRCh37,,,,,missense_variant,"ENST00000357654.3:c.4484G>T,NM_007294.3:c.4484G>T,NP_009225.1:p.Arg1495Met,NC_000017.10:g.41228505C>A",2018-11-30 14:44:11 UTC,0.0,CA002876,37598,"ARG1495MET,R1516M",,,
989,989,https://civic.genome.wustl.edu/links/variants/1248,BRCA2,675,M1I,,,13,32890600.0,32890600.0,G,T,ENST00000544455.1,75.0,GRCh37,,,,,missense_variant,"NC_000013.10:g.32890600G>T,NM_000059.3:c.3G>T,NP_000050.2:p.Met1Ile,ENST00000544455.1:c.3G>T",2018-11-30 14:44:06 UTC,0.0,CA019369,37871,"MET1ILE,RS80358650",,,
992,992,https://civic.genome.wustl.edu/links/variants/1251,BRCA2,675,V211I,,,13,32900751.0,32900751.0,G,A,,,GRCh37,,,,,missense_variant,NC_000013.10:g.32900751G>A,2018-11-30 14:44:12 UTC,0.0,CA023848,,,,,
993,993,https://civic.genome.wustl.edu/links/variants/1252,BRCA2,675,R2336P,,,13,32921033.0,32921033.0,G,C,ENST00000544455.1,75.0,GRCh37,,,,,missense_variant,"NM_000059.3:c.7007G>C,NP_000050.2:p.Arg2336Pro,NC_000013.10:g.32921033G>C,ENST00000544455.1:c.7007G>C",2018-11-30 14:44:12 UTC,0.0,CA024716,52241,"ARG2336PRO,RS28897743",,,
994,994,https://civic.genome.wustl.edu/links/variants/1253,BRCA2,675,R2336H,,,13,32921033.0,32921033.0,G,A,ENST00000544455.1,75.0,GRCh37,,,,,missense_variant,"NM_000059.3:c.7007G>A,NP_000050.2:p.Arg2336His,ENST00000544455.1:c.7007G>A,NC_000013.10:g.32921033G>A",2018-11-30 14:45:05 UTC,0.0,CA024713,38077,"RS28897743,ARG2336HIS",,,
995,995,https://civic.genome.wustl.edu/links/variants/1254,TP53,7157,V143A,,,17,7578502.0,7578502.0,A,G,ENST00000269305.4,75.0,GRCh37,,,,,missense_variant,"ENST00000269305.4:c.428T>C,NC_000017.10:g.7578502A>G",2018-11-30 14:43:03 UTC,0.0,CA397842518,NONE FOUND,VAL143ALA,,,
1001,1001,https://civic.genome.wustl.edu/links/variants/1260,RET,5979,C609Y,"There is some functional evidence that this variant leads to reduced RET activity (PMID: 9230192) and increased cell proliferation and resistance to apoptosis (PMID: 16715139). It has been widely reported in both familial and sporadic cases of multiple endocrine neoplasia type 2 with medullary thyroid cancers. Despite extensive WGS and Exome coverage for a combined total of ~150k alleles in the GNOMAD browser, this variant has never been observed.",,10,43609070.0,43609070.0,G,A,ENST00000355710.3,75.0,GRCh37,,,,,missense_variant,"NM_020630.4:c.1826G>A,NC_000010.10:g.43609070G>A,NP_065681.1:p.Cys609Tyr,ENST00000355710.3:c.1826G>A",2018-11-30 14:43:21 UTC,20.0,CA007824,13933,CYS609TYR,,,
1012,1012,https://civic.genome.wustl.edu/links/variants/1271,ROS1,6098,G2032R,,,6,117638347.0,117638347.0,C,T,ENST00000368508.3,75.0,GRCh37,,,,,missense_variant,"NC_000006.11:g.117638347C>T,NM_002944.2:c.6094G>A,NP_002935.2:p.Gly2032Arg,ENST00000368508.3:c.6094G>A",2018-11-30 14:43:25 UTC,2.5,CA16602597,376139,GLY2032ARG,,,
1026,1026,https://civic.genome.wustl.edu/links/variants/1285,CTNNB1,1499,T41A,,,3,41266124.0,41266124.0,A,G,ENST00000349496.5,75.0,GRCh37,,,,,missense_variant,"NM_001904.3:c.121A>G,NP_001895.1:p.Thr41Ala,NC_000003.11:g.41266124A>G,ENST00000349496.5:c.121A>G",2018-11-30 14:43:58 UTC,55.0,CA127269,17580,"THR41ALA,RS121913412",,,
1027,1027,https://civic.genome.wustl.edu/links/variants/1286,CTNNB1,1499,S45F,,,3,41266137.0,41266137.0,C,T,ENST00000349496.5,75.0,GRCh37,,,,,missense_variant,"NM_001904.3:c.134C>T,NP_001895.1:p.Ser45Phe,NC_000003.11:g.41266137C>T,ENST00000349496.5:c.134C>T",2018-11-30 14:44:05 UTC,60.0,CA127283,17588,"SER45PHE,RS121913409",,,
1029,1029,https://civic.genome.wustl.edu/links/variants/1288,JAK3,3718,M511I,,,19,17949108.0,17949108.0,C,T,ENST00000458235.1,75.0,GRCh37,,,,,missense_variant,"ENST00000458235.1:c.1533G>A,NM_000215.3:c.1533G>A,NP_000206.2:p.Met511Ile,NC_000019.9:g.17949108C>T",2018-11-30 14:44:06 UTC,0.0,CA9301867,NONE FOUND,"MET511I,RS752661478",,,
1030,1030,https://civic.genome.wustl.edu/links/variants/1289,JAK3,3718,V722I,,,19,17945696.0,17945696.0,C,T,ENST00000458235.1,75.0,GRCh37,,,,,missense_variant,"NM_000215.3:c.2164G>A,NP_000206.2:p.Val722Ile,NC_000019.9:g.17945696C>T,ENST00000458235.1:c.2164G>A",2018-11-30 14:44:12 UTC,0.0,CA160225,134573,"VAL722ILE,RS3213409",,,
1068,1068,https://civic.genome.wustl.edu/links/variants/1397,FLT3,2322,D835E,,,13,28592640.0,28592640.0,A,T,,,GRCh37,,,,,missense_variant,,2018-11-30 14:44:13 UTC,0.0,CA16602449,,,,,
1106,1106,https://civic.genome.wustl.edu/links/variants/1509,ABL1,25,BCR-ABL E453Q,,,9,133753888.0,133753888.0,G,C,ENST00000318560.5,75.0,GRCh37,,,,,missense_variant,"ENST00000318560.5:c.1357G>C,NC_000009.11:g.133753888G>C,NM_005157.5:c.1357G>C,NP_005148.2:p.Glu453Gln",2018-11-30 14:45:06 UTC,5.0,CA375251170,NONE FOUND,"E472Q,BCR-ABL GLU453GLN",,,
1186,1186,https://civic.genome.wustl.edu/links/variants/1595,ABL1,25,H201L,,,9,133738202.0,133738202.0,A,T,ENST00000318560.5,75.0,GRCh37,,,,,missense_variant,"ENST00000318560.5:c.602A>T,NC_000009.11:g.133738202A>T,NM_005157.5:c.602A>T,NP_005148.2:p.His201Leu",2018-11-30 14:44:24 UTC,0.0,CA375262464,NONE FOUND,"H220L,HIS201LEU",,,
1236,1236,https://civic.genome.wustl.edu/links/variants/1650,BRAF,673,G596V,,,7,140453148.0,140453148.0,C,A,,,GRCh37,,,,,missense_variant,,2018-11-30 14:44:30 UTC,0.0,CA220161,,"G204V,G24V",,,
1239,1239,https://civic.genome.wustl.edu/links/variants/1653,PIK3CA,5290,D350G,,,3,178921567.0,178921567.0,A,G,ENST00000263967.3,75.0,GRCh37,,,,,missense_variant,"ENST00000263967.3:c.1049A>G,NC_000003.11:g.178921567A>G,NM_006218.2:c.1049A>G,NP_006209.2:p.Asp350Gly",2018-11-30 14:44:35 UTC,2.0,CA355281594,NONE FOUND,ASP350GLY,,,
1241,1241,https://civic.genome.wustl.edu/links/variants/1656,ABL1,25,R351W,,,9,133748333.0,133748333.0,C,T,ENST00000372348.2,75.0,GRCh37,,,,,missense_variant,"ENST00000372348.2:c.1051C>T,NC_000009.11:g.133748333C>T,NM_007313.2:c.1051C>T,NP_009297.2:p.Arg351Trp",2018-11-30 14:44:31 UTC,9.0,CA5285359,NONE FOUND,"R332W,ARG351TRP,RS779478267",,,
1244,1244,https://civic.genome.wustl.edu/links/variants/1659,KIT,3815,S628N,,,4,55594180.0,55594180.0,G,A,,,GRCh37,,,,,missense_variant,,2019-03-23 00:00:11 UTC,0.0,CA356908374,,S624N,,,
1246,1246,https://civic.genome.wustl.edu/links/variants/1661,ALK,238,R1192P,,,2,29443642.0,29443642.0,C,G,ENST00000389048.3,75.0,GRCh37,,,,,missense_variant,"NM_004304.4:c.3575G>C,NP_004295.2:p.Arg1192Pro,NC_000002.11:g.29443642C>G,ENST00000389048.3:c.3575G>C",2018-11-30 14:44:26 UTC,0.0,CA341486,18085,"ARG1192PRO,RS113994089",,,
1271,1271,https://civic.genome.wustl.edu/links/variants/1686,ACVR1,90,G328V,,ACVR1 kinase domain mutation,2,158622516.0,158622516.0,C,A,ENST00000434821.1,75.0,GRCh37,,,,,missense_variant,"NM_001105.4:c.983G>T,NP_001096.1:p.Gly328Val,NC_000002.11:g.158622516C>A,ENST00000434821.1:c.983G>T",2018-11-30 14:45:32 UTC,30.0,CA16602802,376363,"GLY328VAL,RS387906589",9,https://civic.genome.wustl.edu/links/assertions/9,
1280,1280,https://civic.genome.wustl.edu/links/variants/1695,TP53,7157,R158H,,,17,7578457.0,7578457.0,C,T,ENST00000269305.4,75.0,GRCh37,,,,,missense_variant,ENST00000269305.4:c.473G>A,2019-03-13 00:00:10 UTC,4.0,CA000227,NONE FOUND,ARG158HIS,,,
1293,1293,https://civic.genome.wustl.edu/links/variants/1741,VHL,7428,Y98H (c.292T>C),,,3,10183823.0,10183823.0,T,C,ENST00000256474.2,75.0,GRCh37,,,,,missense_variant,"NM_000551.3:c.292T>C,NP_000542.1:p.Tyr98His,NC_000003.11:g.10183823T>C,ENST00000256474.2:c.292T>C",2019-01-11 14:05:28 UTC,47.5,CA020246,2223,"C.292T>C,TYR98HIS,RS5030809",,,
1296,1296,https://civic.genome.wustl.edu/links/variants/1744,VHL,7428,A149T (c.445G>A),,,3,10188302.0,10188302.0,G,A,ENST00000256474.2,75.0,GRCh37,,,,,missense_variant,"ENST00000256474.2:c.445G>A,NM_000551.3:c.445G>A,NP_000542.1:p.Ala149Thr,NC_000003.11:g.10188302G>A",2018-11-30 14:44:52 UTC,5.0,CA357066,223213,"C.445G>A,ALA149THR,RS587780077",,,
1299,1299,https://civic.genome.wustl.edu/links/variants/1747,VHL,7428,R167W (c.499C>T),,,3,10191506.0,10191506.0,C,T,ENST00000256474.2,75.0,GRCh37,,,,,missense_variant,"NM_000551.3:c.499C>T,NP_000542.1:p.Arg167Trp,NC_000003.11:g.10191506C>T,ENST00000256474.2:c.499C>T",2019-03-21 17:19:42 UTC,60.0,CA020450,2218,"C.499C>T,ARG167TRP,R126W,RS5030820",,,
1301,1301,https://civic.genome.wustl.edu/links/variants/1749,VHL,7428,F76I (c.226T>A),,,3,10183757.0,10183757.0,T,A,ENST00000256474.2,75.0,GRCh37,,,,,missense_variant,"ENST00000256474.2:c.226T>A,NC_000003.11:g.10183757T>A,NM_000551.3:c.226T>A,NP_000542.1:p.Phe76Ile",2018-11-30 14:43:12 UTC,0.0,CA351749221,NONE FOUND,"C.226T>A,PHE76ILE",,,
1306,1306,https://civic.genome.wustl.edu/links/variants/1756,VHL,7428,N78T (c.233A>C),,,3,10183764.0,10183764.0,A,C,ENST000,75.0,GRCh37,,,,,missense_variant,"NM_000551.3:c.233A>C,NP_000542.1:p.Asn78Thr,NC_000003.11:g.10183764A>C,ENST00000256474.2:c.233A>C",2018-11-30 14:44:54 UTC,10.0,CA357095,223168,"C.233A>C,ASN78THR,RS5030804",,,
1307,1307,https://civic.genome.wustl.edu/links/variants/1757,VHL,7428,S80I (c.239G>T),,,3,10183770.0,10183770.0,G,T,ENST00000,75.0,GRCh37,,,,,missense_variant,"ENST00000256474.2:c.239G>T,NM_000551.3:c.239G>T,NP_000542.1:p.Ser80Ile,NC_000003.11:g.10183770G>T",2018-11-30 14:44:14 UTC,15.0,CA16621914,NONE FOUND,"C.239G>T,SER80ILE,RS5030805",,,
1420,1420,https://civic.genome.wustl.edu/links/variants/1874,VHL,7428,S80N (c.239G>A),,,3,10183770.0,10183770.0,G,A,ENST00000256474.2,75.0,GRCh37,,,,,missense_variant,"ENST00000256474.2:c.239G>A,NC_000003.11:g.10183770G>A,NM_000551.3:c.239G>A,NP_000542.1:p.Ser80Asn",2018-11-30 14:44:36 UTC,25.0,CA70046108,NONE FOUND,"C.239G>A,SER80ASN,RS5030805",,,
1445,1445,https://civic.genome.wustl.edu/links/variants/1904,VHL,7428,S72P (c.214T>C),,,3,10183745.0,10183745.0,T,C,ENST,75.0,GRCh37,,,,,missense_variant,"NM_000551.3:c.214T>C,NP_000542.1:p.Ser72Pro,NC_000003.11:g.10183745T>C,ENST00000256474.2:c.214T>C",2018-11-30 14:44:37 UTC,10.0,CA357006,223163,"C.214T>C,SER72PRO,RS869025618",,,
1457,1457,https://civic.genome.wustl.edu/links/variants/1916,VHL,7428,R167L (c.500G>T),,,3,10191507.0,10191507.0,G,T,ENST00000256474.2,75.0,GRCh37,,,,,missense_variant,"NC_000003.11:g.10191507G>T,NM_000551.3:c.500G>T,NP_000542.1:p.Arg167Leu,ENST00000256474.2:c.500G>T",2019-02-18 10:39:31 UTC,7.5,CA351756178,526685,"C.500G>T,ARG167LEU",,,
1482,1482,https://civic.genome.wustl.edu/links/variants/1941,VHL,7428,S168T (c.503G>C),,,3,10191510.0,10191510.0,G,C,ENST,75.0,GRCh37,,,,,missense_variant,"ENST00000256474.2:c.503G>C,NC_000003.11:g.10191510G>C,NM_000551.3:c.503G>C,NP_000542.1:p.Ser168Thr",2018-11-30 14:45:10 UTC,0.0,CA351756183,NONE FOUND,"C.503G>C,SER168THR",,,
1487,1487,https://civic.genome.wustl.edu/links/variants/1946,VHL,7428,Y156C (c.467A>G),,,3,10191474.0,10191474.0,A,G,ENST00000256474.2,75.0,GRCh37,,,,,missense_variant,"NM_000551.3:c.467A>G,NP_000542.1:p.Tyr156Cys,NC_000003.11:g.10191474A>G,ENST00000256474.2:c.467A>G",2019-03-21 20:21:39 UTC,20.0,CA020394,43600,"C.467A>G,TYR156CYS,RS397516441",,,
1506,1506,https://civic.genome.wustl.edu/links/variants/1966,VHL,7428,W88S (c.263G>C),,,3,10183794.0,10183794.0,G,C,ENST00000256474.2,75.0,GRCh37,,,,,missense_variant,"NM_000551.3:c.263G>C,NP_000542.1:p.Trp88Ser,NC_000003.11:g.10183794G>C,ENST00000256474.2:c.263G>C",2018-11-30 14:45:11 UTC,7.5,CA020202,2220,"C.263G>C,TRP88SER,RS119103277",,,
1507,1507,https://civic.genome.wustl.edu/links/variants/1967,VHL,7428,Y156D (c.466T>G),,,3,10191473.0,10191473.0,T,G,ENST00000256474.2,75.0,GRCh37,,,,,missense_variant,"ENST00000256474.2:c.466T>G,NC_000003.11:g.10191473T>G,NM_000551.3:c.466T>G,NP_000542.1:p.Tyr156Asp",2018-11-30 14:44:39 UTC,7.5,CA351756043,NONE FOUND,"C.466T>G,TYR156ASP",,,
1854,1854,https://civic.genome.wustl.edu/links/variants/2330,ERBB2,2064,L869R,,,17,37881414.0,37881414.0,T,G,ENST00000269571.5,75.0,GRCh37,,,,,"missense_variant,gain_of_function_variant","NC_000017.10:g.37881414T>G,NM_004448.3:c.2606T>G,NP_004439.2:p.Leu869Arg,ENST00000269571.5:c.2606T>G",2018-11-30 14:45:31 UTC,0.0,CA399304956,431024,LEU869ARG,,,
